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Abstract 
Porcine epidemic diarrhea virus (PEDv) causes disease and mortality to piglets worldwide. 
Most vaccines used to combat the disease have been ineffective live attenuated virus 
vaccines. The goal of this project was to produce a plant-made subunit vaccine based off the 
membrane protein of the virus. This is the first time this protein has been produced in plants. 
An elastin-like polypeptide fusion membrane protein accumulated up to 0.8 mg/g of fresh 
leaf weight when transiently expressed in Nicotiana benthamiana. Virus-like particles were 
also produced for the first time for PEDv, and were able to form with just the membrane 
protein, or from co-expression of the membrane and envelope protein. This adds to the 
limited body evidence that the membrane protein is the only necessary component to make 
coronavirus-like particles, and represents the first time coronavirus-like particles have been 
made in plants. 
Keywords 
Porcine epidemic diarrhea virus, recombinant protein, subunit vaccine, membrane protein, 
envelope protein, coronavirus, virus-like particle, plant biotechnology, Nicotiana 
benthamiana 
  
  
 iii   
 
Acknowledgments 
Thank you for teaching me…  
First, my supervisor, Dr. Rima Menassa: …that good things can come when you believe in 
people. It was a genuine pleasure being your student. 
My co-supervisor, Dr. Susanne Kohalmi: …that guidance paired with a smile goes a long 
way. 
My advisors, Dr. Aiming Wang and Dr. Rob Cumming: …to be critical always, and hold 
myself to the highest standards. 
Dr. Justin Renaud: …mass spectrometry, and for his assistance with mass spectrometry 
analysis.   
Karen Nygard and Dr. Richard Gardiner: …how to perform TEM analysis, and use of the 
Biotron Experimental Climate Change Research Centre facilities.  
Dr. Norm Hüner and Beth Szyszka: …how to use an ultracentrifuge, and allowing me to use 
theirs. 
Alex Molnar: …how to make a beautiful figure, and for his assistance in figure preparation.  
Angelo and Hong: …for everything I know about labwork. Truly. 
Reza: …that hard work can be paired with a little goofiness. 
The Menassa lab – Adam, Coby, Igor, Israel, Jacqueline, Jenny, Kira, Livia, Sean: …that 
good friends make work a pleasure. 
Emily: …that some people are crazy enough to support me at all hours of the day.  
Everybody in the department, and all my friends at AgCan: …the power of a community. 
And most of all, thank you to my family and close friends for teaching me that good things 
take time, patience, and little bit of love and support. 
  
 iv   
 
Table of Contents 
Abstract ............................................................................................................................... ii 
Acknowledgments.............................................................................................................. iii 
Table of Contents ............................................................................................................... iv 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Appendices .............................................................................................................. x 
List of Abbreviations ......................................................................................................... xi 
1 Introduction .................................................................................................................... 1 
1.1 Vaccine Design ....................................................................................................... 1 
1.1.1 Virus-Like Particles .................................................................................... 2 
1.1.2 Platforms for Recombinant Protein Expression .......................................... 3 
1.1.2.1 Plants as Bioreactors ..................................................................... 3 
1.1.2.2 Plant-Made VLPs ......................................................................... 4 
1.1.3 PEDv Vaccine Design................................................................................. 5 
1.1.3.1 PEDv Structure ............................................................................. 6 
1.1.3.2 Existing PEDv Commercial Vaccines .......................................... 9 
1.1.3.3 S Protein ..................................................................................... 10 
1.1.3.4 M Protein .................................................................................... 13 
1.1.3.4.1 Structure and Conservation ......................................................... 13 
1.1.3.4.2 Antigenicity of M Protein ............................................................ 13 
1.1.3.4.3 Role in Viral Assembly ............................................................... 15 
1.1.3.4.4 M is Crucial for VLP Formation ................................................. 16 
1.1.3.4.5 Previous Recombinant Expression .............................................. 16 
1.2 Membrane Protein Expression and Extraction ..................................................... 18 
  
 v   
 
1.2.1 Importance of Detergents .......................................................................... 19 
1.2.1.1 Detergent Properties ................................................................... 19 
1.2.1.2 Detergent Types .......................................................................... 19 
1.3 Hypothesis and Objectives .................................................................................... 21 
2 Materials and Methods ................................................................................................. 22 
2.1 Gene Synthesis ...................................................................................................... 22 
2.2 Transient Assays ................................................................................................... 22 
2.2.1 Composition of Cloning and Infiltration Reagents ................................... 22 
2.2.2 Gateway Cloning® ................................................................................... 22 
2.2.3 Golden Gate Cloning ................................................................................ 24 
2.2.4 E. coli Transformation .............................................................................. 24 
2.2.5 Agrobacterium tumefaciens Transformation ............................................ 25 
2.2.6 Transient Expression in Nicotiana benthamiana....................................... 25 
2.2.7 Small Scale Tissue Collection and Protein Extraction ............................. 26 
2.2.8 Large Scale Tissue Collection and Protein Extraction and Concentration 
for VLP Detection ..................................................................................... 29 
2.2.9 Western Blotting Procedure ...................................................................... 30 
2.3 Protein Quantification ........................................................................................... 32 
2.4 VLP Analysis ........................................................................................................ 32 
2.4.1 Transmission Electron Microscopy .......................................................... 32 
2.4.2 TEM Immunogold Labeling ..................................................................... 33 
2.5 Mass Spectrometry................................................................................................ 33 
2.6 In Silico Sequence Analysis.................................................................................. 36 
2.6.1 Protein Structure Analysis ........................................................................ 36 
2.6.2 VLP Structure Analysis ............................................................................ 36 
3 Results .......................................................................................................................... 37 
  
 vi   
 
3.1 Transient Expression of M .................................................................................... 37 
3.1.1 Optimal Construct Choice......................................................................... 37 
3.1.2 Extraction and Detection Choice .............................................................. 40 
3.2 VLP Formation ..................................................................................................... 49 
3.2.1 In silico Analysis of M and M-ELP .......................................................... 49 
3.2.2 Expression of S, N, E, and Co-Expression ............................................... 53 
3.2.3 VLP Formation ......................................................................................... 61 
3.2.3.1 Sucrose Gradient Analysis ......................................................... 61 
3.2.3.2 VLP Analysis .............................................................................. 64 
4 Discussion .................................................................................................................... 67 
4.1 PEDv vaccine design ............................................................................................ 67 
4.2 Transient production of M .................................................................................... 67 
4.3 Extraction of M-ELP............................................................................................. 68 
4.3.1 Peroxidase ................................................................................................. 70 
4.4 PEDv S, N, and E, and Co-Expression ................................................................. 72 
4.5 Virus-Like Particles .............................................................................................. 74 
4.5.1 Formation Requirements ........................................................................... 74 
4.5.2 CoVLP Structure ....................................................................................... 77 
4.5.3 CoVLP Size .............................................................................................. 77 
4.5.4 CoVLP Sedimentation Analysis ............................................................... 78 
4.5.5 CoVLP Immunogenicity ........................................................................... 80 
5 Outlook ......................................................................................................................... 82 
References ......................................................................................................................... 83 
Appendices ........................................................................................................................ 97 
Curriculum Vitae .............................................................................................................. 99 
 
  
 vii   
 
List of Tables 
Table 1. Production of S-COE in plants1. ............................................................................... 11 
Table 2. List of all work on recombinant expression of PEDv M protein. ............................. 17 
Table 3.  Recipes for cloning and infiltration reagents ........................................................... 23 
Table 4. Composition of various buffers used for protein extraction1,2. ................................. 27 
Table 5. Reagents used for Western blotting procedures. ...................................................... 31 
Table 6. Reagents used for mass spectrometry methods. ....................................................... 34 
Table 7. Protein extraction levels with different detergents/disruptants. ................................ 47 
Table 8. Protein extraction levels with lab and commercial buffers. ...................................... 50 
Table 9. Protein expression configurations resulting in CoVLP assembly. ........................... 76 
 
  
 viii   
 
List of Figures 
Figure 1. A schematic of the genome of PEDv. ....................................................................... 7 
Figure 2. A schematic of an assembled PEDv virus, and a PEDv VLP. .................................. 8 
Figure 3. Schematics of the gene constructs used for N. benthamiana expression. ............... 38 
Figure 4. Western blot of M expressed with various expression constructs. .......................... 39 
Figure 5. Extraction of infiltrated constructs with commercial membrane protein extraction 
kit. ........................................................................................................................................... 41 
Figure 6. M-ELP extracted with commercial kit, and both boiled and unboiled. ................... 42 
Figure 7. Dot blot showing presence of plant peroxidase in unboiled protein extracts. ......... 44 
Figure 8. Western blot detected before and after probing to look for peroxidase activity. .... 45 
Figure 9. Comparison of protein extraction levels with different detergents/disruptants. ...... 48 
Figure 10. Visual comparison of differences in Triton X-100 based buffers. ........................ 51 
Figure 11. Predicted protein structures of M and M-ELP. ..................................................... 52 
Figure 12. Expression of all four PEDv structural genes........................................................ 54 
Figure 13. All four structural genes, individually and co-expressed, with ECL substrate 
before and after antibody hybridization. ................................................................................. 56 
Figure 14. N. benthamiana leaf infiltrated with M-ELP, E-ELP, or M-ELP and E-ELP. ...... 59 
Figure 15. Co-expression of PEDv proteins, and time course. ............................................... 60 
Figure 16. Protein extract ultracentrifuged through a sucrose gradient. ................................. 62 
Figure 17. Immunoblot analysis of sucrose gradient fractions of M-ELP and M-ELP+E-ELP 
protein extracts. ....................................................................................................................... 63 
  
 ix   
 
Figure 18. TEM and Immungold TEM analysis of 40% sucrose gradient fractions. ............. 65 
 
  
 x   
 
List of Appendices 
Appendix A. Example of a dot blot used for quantification, with standards, M-ELP and p19 
(negative control) tissue. ......................................................................................................... 97 
Appendix B. Mass spectrometry analysis of digested protein extracts. ................................. 98 
 
  
  
 xi   
 
List of Abbreviations 
3CL 3C-like proteinase 
a.a. Amino acid 
AEBSF 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride 
AGC Automatic gain control 
ANOVA Analysis of variance 
APC Antigen presenting cell 
Apo Apoplast 
ATP Adenosine triphosphate 
Bp Base pair 
BSA Bovine serum albumin 
CaMV Cauliflower mosaic virus 
CBD Cellulose binding domain 
CCoV Canine coronavirus 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CHO Chinese hamster ovary  
COE CO-26K equivalent 
CoVLP Coronavirus-like particle 
CTAB Cetrimonium bromide 
DIVA Distinguish infected from vaccinated animals 
  
 xii   
 
DMSO Dimethyl sulfoxide 
DSB Detergent screen buffer 
DTT Dithiothreitol 
E Envelope protein 
ECL Enhanced chemoluminescence 
EDTA Ethylenediaminetetraccetic acid 
ELP Elastin-like polypeptide 
ER Endoplasmic reticulum 
ERGIC Endoplasmic reticulum intermediate compartment 
FCoV Feline coronavirus 
FEB Final extraction buffer 
GOI Gene of interest 
GST Glutathione S-transferase 
HCoV Human coronavirus 
HEK293 Human embryonic kidney 293 cells 
HFBI Hydrophobin 
His Histidine 
HRP Horseradish peroxidase 
IBV Avian infectious bronchitis virus  
IFN-α Alpha interferon 
  
 xiii   
 
IgA Immunoglobulin A 
IgG  Immunoglobulin G 
IT Injection time 
Kb Kilobase 
kDa Kilodalton 
KDEL ER retrieval signal 
L Linker 
LB Lysogeny broth 
M Membrane protein 
MES 2-(N-morpholino)ethanesulfonic acid 
MHC Major histocompatibility complex 
MHV Mouse hepatitis virus 
N Nucleocapsid protein 
Nos Nopaline synthase 
OD Optical density 
PAR Photosynthetically active radiation 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PEB Protein extraction buffer 
PED Porcine epidemic diarrhea 
  
 xiv   
 
PEDv Porcine epidemic diarrhea virus 
PEG Poly(ethyleneglycol) 
pI Isoelectric point 
PLP Papain-like proteinase 
PMSF Phenylmethanesulfonylfluoride 
Pr1b Pathogenesis-related signal peptide 1b of tobacco 
PTGS Post-translational gene silencing 
PTM Posttranslational modification 
PVDF Polyvinylidene difluoride 
PVPP Polyvinylpolypyrrolidone 
S Spike protein 
SARS-CoV Severe acute respiratory syndrome-associated coronavirus 
SDS Sodium dodecyl sulfate 
TBS Tris-buffer saline 
TBS-T Tris-buffer saline-Tween-20 
TCoV Turkey coronavirus 
tCUP Tobacco cryptic upstream promoter 
TEM Transmission electron microscopy 
TEV Tobacco etch virus 
TGEV Transmissible gastroenteritis coronavirus 
  
 xv   
 
TMV Tobacco mosaic virus 
TSP Total soluble protein 
UPR Unfolded protein response 
UTR Untranslated region 
VLP Virus-like particle 
v/w volume per weight 
w/v weight per volume 
w/w weight by weight 
 
 
 
 
  
1 
  
1 Introduction  
Porcine epidemic diarrhea virus (PEDv) is a coronavirus that causes porcine epidemic 
diarrhea (PED), a disease which affects pigs, and in particular, newly born piglets. PEDv 
has struck around the world, with the first known outbreaks occurring in Europe in the 
1970s. PEDv later spread to Asia, where it was first detected in Japan in 1982, and then 
in South Korea, China, and Thailand (Chen et al., 2014). Since October 2010 China has 
seen a severe outbreak of PEDv, resulting in high porcine mortality rates and economic 
losses (Sun et al., 2012). PEDv was first detected in the United States (U.S.) in May of 
2013 (Stevenson et al., 2013) and in Canada in January of 2014 (Ojkic et al., 2015). The 
serotypes identified in North America are most closely related to a recently emerged 
Chinese serotype (Huang et al., 2013). 
PEDv causes the destruction of villus enterocytes and atrophy of intestinal villi. The 
disease is 95% fatal for neonatal piglets in naïve unvaccinated herds (Stevenson et al., 
2013). The death of millions of suckling piglets and diarrhea-derived weight loss in 
fattening pigs caused severe economic losses in the U.S. and Canada (Chen et al., 2014). 
An effective vaccine is needed against PEDv, but no vaccines are available in Canada, 
and only two vaccines with unknown efficacy have conditional approval in the U.S. (see 
section 1.1.3.2 below). 
1.1 Vaccine Design 
Vaccines can be live attenuated viruses, inactivated viruses, or subunit vaccines. While 
live attenuated viruses have been used commercially, they potentially can mutate and 
become pathogenic again. They allow for genome segment re-assortment between 
vaccine and field strains, resulting in potentially dangerous new strains (reviewed in 
Calvo-Pinilla et al., 2014). One Chinese field strain of PEDv is thought to have 
potentially evolved from a live attenuated vaccine (Chen et al., 2010). Attenuated strains 
may not replicate enough to induce protective immunity at viral infection site (Saif, 
1993). Inactivated viruses raise concerns over reliability of inactivation, and have a high 
cost of production (Calvo-Pinilla et al., 2014). With either live attenuated viruses or 
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inactivated viruses, serological testing to “distinguish infected from vaccinated animals” 
(DIVA) assays are not reliable. Subunit vaccines present a stable and safe alternative, as 
they are synthesized proteins that are not directly derived from live viruses. As isolated 
molecules they also lack genetic material avoiding any possibility for virulence or 
mutation. Subunit vaccines for infectious bronchitis virus, a gammacoronavirus, were 
shown to induce higher immune responses than inactivated virus vaccines when both 
were injected (Liu et al., 2013).   
1.1.1 Virus-Like Particles  
Subunit vaccines, while safer than inactivated or live attenuated vaccines, do not always 
have high immunogenicity. Virus-like particles (VLPs) represent advancements in 
subunit vaccine development, showing higher immunogenicity. VLPs are structures made 
up of assembled viral proteins that resemble the morphology of their respective pathogen 
(reviewed by Kushnir et al., 2012). Like other subunit vaccines, they benefit from being 
non-replicative and non-infectious due to not having any genetic material. In addition, 
VLPs display viral protein epitopes in correct conformations, and as exogenous, 
particulate antigens, are processed and presented on antigen presenting cells (APC) by 
MHC class I or II molecules. This means that they can effectively stimulate humoral and 
cellular immune responses as the native viruses would, and do not require the use of 
adjuvants (reviewed by Grgacic and Anderson, 2006). It is also important that VLPs can 
target dendritic cells, APCs involved in innate and adaptive immunity. Dendritic cell 
stimulation for cytokine production requires an intact virion. Here VLPs have an 
advantage over live attenuated and inactivated viruses, as both are shown to interfere with 
dendritic cell activation (reviewed by Grgacic and Anderson, 2006).  
One vaccine success story involves hepatitis B virus-like particles. In the 1980s, existing 
products on the market were expensive, and limited in supply. VLPs based on hepatitis B 
small surface antigen were produced in yeast at a cheaper cost, which continued to 
decrease, allowing 110 countries to routinely immunize infants for hepatitis B today 
(reviewed by Rybicki, 2014). Almost all recombinant vaccines available for humans are 
VLP based, including GlaxoSmithKline’s Cervarix® (against human papilloma virus) 
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(GlaxoSmithKline, 2014), and Merck and Co., Inc’s Recombivax HB® (against hepatitis 
B virus) (Merck, 2011b) and Gardasil® (against human papilloma virus) (Merck, 2011a). 
1.1.2 Platforms for Recombinant Protein Expression 
To produce subunit vaccines, a suitable platform must be chosen for recombinant protein 
production. While bacteria are commonly used to produce recombinant proteins, use of 
bacteria is not preferred due to differences with eukaryotes in their protein-folding 
machinery (Jacob et al., 2007), absence of a mammalian-like posttranslational 
modifications (PTM) such as glycosylation, and risk of bacterial endotoxin contamination 
of the final product (reviewed by Kushnir et al., 2012). Bacteria are used to produce non-
enveloped VLPs, but not enveloped VLPs (reviewed by Kushnir et al., 2012). 
Mammalian cell lines such as Chinese hamster ovary (CHO) and human embryonic 
kidney 293 (HEK293) cells are currently the gold standard for biopharmaceutical 
production, but are expensive and bear the risk of harboring mammalian pathogens 
(Fischer et al., 2012). Research has shown that plants are also an efficient platform for the 
production of recombinant proteins (reviewed by Rybicki, 2014). 
1.1.2.1 Plants as Bioreactors 
Plants have numerous advantages as a platform for recombinant protein production. This 
platform is easily scalable, and safe from mammalian and bacterial pathogens (Menassa 
et al., 2012). Plants have the capability to fold and glycosylate complex proteins and can 
be grown in greenhouses using current farming techniques (Fischer et al., 2012; Menassa 
et al., 2012). Plants allow for an easy delivery method for vaccines, as plants can be fed 
without processing or extracting the protein. It is believed that plant components, 
including the plant cell matrix, can act as adjuvants, stimulating antigen-specific and non-
specific immune responses (Bae et al., 2003). The plant cell wall also protects the antigen 
from degradation in the gastro-intestinal tract. Proteins are then released in the gut lumen, 
and can cross the intestinal epithelium with the use of tags that utilize endocytic 
subpathways (reviewed by Kwon and Daniell, 2016). This property is useful for a PEDv 
vaccine, as the epithelium is the major area of disease. In addition, recombinant proteins 
are stable in lyophilized plant tissue stored at room temperature, thus shrinking the 
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storage capacity needed, and simultaneously killing most microbes (Lakshmi et al., 
2013). The ability to orally feed lyophilized plant tissue means reduced costs of 
purification, refrigeration and transport, allowing increased access in developing 
countries hit by PEDv (Lakshmi et al., 2013).   
One plant bioreactor that has been widely studied is Nicotiana benthamiana, as it is 
amenable to transient expression using Agrobacterium tumefaciens (Conley et al., 2011). 
Transient expression does not require the transgene to integrate into the nuclear genome, 
and allows for quick production of recombinant proteins, with no generation of 
genetically modified plants. This is an advantage that regulatory bodies look favourably 
upon, due to reduced risk for transgene dissemination via pollen or seed (reviewed by 
Rymerson et al., 2002). N. benthamiana is also a good platform for transient recombinant 
protein production due to its small size and quick growth (Conley et al., 2011). 
N. benthamiana is also advantageous from a regulatory standpoint as it is not a food or 
feed plant, reducing the risk of contaminating the food chain (reviewed by Rymerson et 
al., 2002). One highly publicized story of this platform has been with the production of 
monoclonal antibodies against Ebola. Three Ebola-specific mouse-human chimeric 
monoclonal antibodies were transiently produced in N. benthamiana using the 
magnICON tobacco mosaic virus (TMV)-based viral vectors (Gleba et al., 2005). Plant-
produced antibodies were three times as potent as those produced in CHO cells. These 
antibodies were used in a cocktail of anti-Ebola monoclonal antibodies called ZMapp, 
which were shown to rescue 100% of rhesus macaques when administered five days post 
live virus challenge (Qiu et al., 2014). ZMapp was an important player in the recent 
Ebola outbreak, used to save the lives of two U.S. healthcare workers that had contracted 
Ebola (reviewed by Rybicki, 2014).  
1.1.2.2 Plant-Made VLPs 
Enveloped VLPs acquire lipid envelopes, characteristically with embedded immunogenic 
glycoproteins, when they bud off. Therefore, they are only produced in eukaryotic 
systems (Lua et al., 2014). Plants are capable of producing both enveloped and non-
enveloped VLPs. Enveloped plasma membrane-derived VLPs for influenza were 
produced through transient expression in N. benthamiana, and these VLPs were able to 
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confer complete protection to mice against a lethal challenge, even though mice were 
challenged with a genetically dissimilar strain. It was also found that immunization with 
these VLPs induced antibody responses four- to six-fold higher than when compared to 
immunization with fifty times more of flu antigen not in VLPs (D'Aoust et al., 2008).  
Complex non-enveloped VLPs have also been produced, including for bluetongue 
disease, which causes lameness and mortality in ruminants. VLPs for bluetongue virus 
(BTV) required simultaneous expression of four different proteins in varying amounts. 
N. benthamiana was used for transient expression using the pEAQ expression vector 
system, and the VLPs were able to elicit antibody response, and provide protective 
immunity (Thuenemann et al., 2013). Medicago Inc., a Canadian company, is a success 
story of plant-made VLPs, using a fully automated greenhouse to efficiently agroinfiltrate 
large numbers of N. benthamiana plants. Medicago Inc. is on track to produce ten million 
doses of VLP pandemic influenza vaccine per month (Medicago, 2016). 
VLP purification can be very challenging, and despite advances geared towards purifying 
large scale amounts, technical challenges persist in ensuring no contaminating DNA or 
proteins are trapped in the VLPs and that VLPs are homogenous (reviewed by Lua et al., 
2014).  Additionally, although VLPs are self-adjuvanting, currently all licensed VLP-
based vaccines are formulated with aluminum salts, an adjuvant (reviewed by Lua et al., 
2014). As plant components are believed to have adjuvanting ability (Kolotilin et al., 
2014), plant cell-encapsulated VLPs may not need additional adjuvants. VLP structure 
and immunogenicity is preserved when plant tissue is lyophilized, and shown to be stable 
for at least one year (Czyz et al., 2014). Lyophilized tissue as a delivery system then may 
be cost-effective, foregoing both VLP purification, and potentially the use of additional 
adjuvants, as well as requiring less storage capacity as previously discussed (1.1.2.1).  
1.1.3 PEDv Vaccine Design 
With the economic losses incurred around the world due to PEDv, the importance of an 
effective vaccine to prevent PED has gained importance. When piglets are first born, 
their immune system is not fully developed and they cannot be vaccinated. However, 
when sows are vaccinated IgA immunocytes secrete IgA antibodies into the colostrum 
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and milk, passing on passive lactogenic immunity to suckling pigs (Bae et al., 2003). It 
has been suggested that aside from the fecal-oral route of transmission, piglets may also 
be infected through vertical transmission of PEDv from sow milk (Sun et al., 2012). 
Vaccinating sows would both prevent vertical transmission of PEDv, and also provide 
passive immunity. These characteristics need to be considered when designing a PEDv 
vaccine.  
1.1.3.1 PEDv Structure 
To produce an effective subunit vaccine for PEDv, the coronavirus structure must be 
understood. The Coronavirinae subfamily consists of three genera: alphacoronavirus, 
betacoronavirus, and gammacoronavirus. PEDv is an enveloped alphacoronavirus 
encoded by a 28 kilobase single-stranded, positive-sense RNA genome (Song and Park, 
2012). Coronaviruses have the largest known RNA genomes of all viruses (King, 2011). 
The genome has a 5’ cap, a 3’ polyadenylated tail and seven open reading frames 
(ORFs), which code for three non-structural proteins (ORF 1a, ORF1b, and ORF3), and 
four structural proteins (spike (S), envelope (E), membrane (M) and nucleocapsid (N)) 
(Figures 1, 2, Figure 2 designed based on reports of protein abundance below) (Song and 
Park, 2012). The two overlapping open reading frames, ORF1a and ORF1b code for two 
polyproteins. These are processed by three virus-encoded proteases, a 3C-like proteinase 
(3CLpro) and two papain-like proteinases (PLP) which results in 16 non-structural 
proteins required for genome replication and mRNA transcription (John et al., 2016; 
reviewed by Prentice et al., 2004). The accessory protein ORF3 is a potassium ion 
channel, but its role is not well defined (Wang et al., 2012). Of the four structural 
proteins, S and M are the proteins considered most important for antigenicity. Reports on 
transmissible gastroenteritis coronavirus (TGEV), another alphacoronavirus, indicate that 
S and E are only present in the virion in small quantities, with E estimated to occur 20 
times in a virion (Godet et al., 1992), while N and M occur in higher numbers, at a ratio 
of 1N:3M (King, 2011). A recent study examining mouse hepatitis virus (MHV), a 
betacoronavirus, severe acute respiratory syndrome-coronavirus (SARS-CoV), a 
betacoronavirus, and feline coronavirus (FCoV), an alphacoronavirus, has determined  
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Figure 1. A schematic of the genome of PEDv.  
The first two ORFs from the 5’ end of the genome cover two thirds of the genome. The 
first codes for polyprotein 1a, and the second for polyprotein 1b. Towards the 3’ end, the 
S protein is then coded for, followed by ORF3, E, M, and finally the N protein. 
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Figure 2. A schematic of an assembled PEDv virus, and a PEDv VLP.  
(a) The nucleocapsid protein (N, red squares) in the centre forms a ribonucleoprotein 
complex with viral RNA (black line). The envelope protein (E, pink) is embedded in the 
membrane (darker grey) as is the membrane protein (M, green), which is the most 
abundant envelope component, encompassing an amino-terminal domain outside the 
virus, three transmembrane segments, and a longer carboxy-terminal domain inside the 
virus. The spike protein (S, blue) also embeds in the membrane, and forms surface 
projections, or ‘spikes’. (b) A theoretical PEDv VLP is smaller in diameter, and forms 
with the M and E proteins.  
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coronaviruses have approximately 1100 M dimers, 90 S trimers, and N proteins in a ratio 
from 3M:1N to 1M:1N (Neuman et al., 2011). Thus, M is the most abundant structural 
protein displayed at the viral surface. 
1.1.3.2 Existing PEDv Commercial Vaccines 
Much of the research done in developing PEDv vaccines has occurred in Asia, where 
outbreaks have been most severe, but none of the produced vaccines are completely 
effective on Asian PEDv strains (Song and Park, 2012). Available Asian vaccines are 
based on strains that are genetically different from those sequenced in the U.S. (Huang et 
al., 2013).   
Two PEDv vaccines were given conditional licenses in the U.S. by the United States 
Department of Agriculture (USDA). The first was a vaccine originally produced by 
Harrisvaccines, Inc. This vaccine is based on their SirraVaxSM RNA platform. Using this 
platform, part of the RNA genome of a Venezuelan equine encephalitis alphavirus is 
replaced with a gene for PEDv S protein. The resulting RNA particle looks like the 
alphavirus, but carries the S gene. After injection, the pig’s dendritic cells produce the S 
protein and an immune response is launched against the produced protein 
(Harrisvaccines, 2015). Merck Animal Health acquired Harrisvaccines in 2015 (Merck 
Animal Health, 2015), but the product is still sold under a conditional license in the U.S., 
where safety and field trials are ongoing. The second is an inactivated virus particle 
vaccine produced by Zoetis, Inc. (Zoetis, 2014). Efficacy and potency studies are still in 
progress for the Zoetis vaccine, and duration of immunity has not been evaluated. It must 
be refrigerated, and used all at once when opened (Zoetis, 2016). Neither vaccine is sold 
in Canada – veterinarians have to apply for an import permit from the Canadian Food 
Inspection Agency to bring batches of the drugs into the country (Merck Animal Health, 
Personal Communication 2016; Zoetis, Personal Communication, 2016). There is one 
Canadian research organization that is testing a prototype PEDv vaccine (Brusky, 2016) 
None of the PEDv vaccines used commercially, at least in the U.S. and Canada, are made 
in planta. The ability to vaccinate orally through feeding plant tissue is important as Song 
et al. (2007) demonstrated that oral vaccination was more effective than injection for their 
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PEDv vaccine. When comparing oral to intramuscular administration of their attenuated 
virus vaccine, Song et al. found that more IgA’s were produced by orally vaccinated pigs, 
and that the mortality rate for this group was 13% in comparison to 60% for the 
intramuscular group.  
1.1.3.3 S Protein 
To date, the S protein has been the primary focus of subunit vaccine design. This is due 
to its antigenicity and the role it plays in viral entry, as it regulates interactions with host 
cell receptor proteins (reviewed by Song and Park, 2012). An epitope capable of inducing 
virus-neutralizing antibodies, called CO-26K equivalent (COE), was identified through 
sequence homology with transmissible gastroenteritis coronavirus (TGEV) (Chang et al., 
2002) at amino acids (a.a.) 1495-1914. Another motif (1368-1374 a.a.; Cruz et al., 2008) , 
as well as the epitope region (636-789 a.a.) have been found to induce the production of 
neutralizing antibodies (Sun et al., 2006).  
However, the use of S is problematic, as it was shown to be prone to mutations through 
serial passages (Sato et al., 2011), and has high genetic variability among different PEDv 
strains. In fact, this variability is utilized to study genetic relatedness of different PEDv 
strains (Chen et al., 2014). This genetic variation, particularly apparent in attenuated 
strains, and importantly, in the epitope, may impact the efficacy of live attenuated virus 
vaccines (Sun et al., 2014). Strains have even been found where 582 nucleotides were 
deleted from the S gene (Masuda et al., 2015). The failure of vaccines on the market may 
be attributed to differences in the sequence of S between the delivered vaccine and 
infectious strain (Sun et al., 2012).   
The majority of recombinant production of the spike protein has been performed in 
plants. Recombinant PEDv protein production in plants has only focused on producing 
the S-COE epitope, and is summarized in Table 1. Plant made S-COE is able to elicit 
antibodies. Bae et al. (2003) produced transgenic tobacco plants expressing the S-COE at 
levels of 10 mg/kg of wet weight. They demonstrated that feeding ground lyophilized 
transgenic tobacco leaves with S antigen suspended in phosphate buffered saline (PBS)  
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Table 1. Production of S-COE in plants1. 
Plant Host Transient or 
Transgenic 
Fusions Yield Promoter and/or 
Enhancer Used 
Reference 
Nicotiana 
tabacum 
Transgenic - 10 mg/kg of 
protein per 
fresh 
weight2 
2x35S, TOL (Bae et al., 
2003)3 
N. tabacum Transient - 5% TSP TMV RNA (Kang et al., 
2004) 
No-nicotine 
N. tabacum 
Transgenic - 2.1% TSP 2x35S, TOL (Kang et al., 
2005a) 
N. tabacum Transgenic - 0.1% TSP 2x35S, TOL (Kang et al., 
2005b) 
Solanum 
tuberosum 
Transgenic - 0.1% TSP 2x35S, TOL (Kim et al., 
2005) 
Lemna minor Transgenic - Not reported 35S (Ko et al., 
2011) 
Ipomoea 
batatas 
Transgenic - Not reported 35S (Yang et al., 
2005) 
Zea mays 
seed 
Transgenic - 0.122% TSP 2x35S, maize 
intron Hsp70 
(Kun et al., 
2014)* 
Daucus 
carota 
Transgenic - Not reported 2x35S, TOL (Kim et al., 
2003) 
Lactuca 
sativa 
Transgenic LTB 0.048% TSP Ubiquitin 
promoter 
(Huy et al., 
2009) 
Oryza sativa 
endosperm 
Transgenic LTB 1.3% TSP HMW-Bx17-p, 
Act1-i 
(Oszvald et 
al., 2007) 
Oryza sativa 
endosperm 
Transgenic LTB 1.9% TSP HMW-Bx17-p, 
Act1-i 
(Tamás, 
2010) 
N. tabacum Transgenic LTB 1.6% TSP Ubiquitin 
promoter 
(Kang et al., 
2006) 
Oryza sativa 
calli 
Transgenic Co1 0.083% TSP RAmy3D  (Huy et al., 
2012)3 
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12x, duplicated; 35S, cauliflower mosaic virus (CaMV) 35S promoter; Act1-I, rice actin 
first intron; Co1, M cell-targeting ligand; HMW-Bx17-p, wheat high molecular weight 
glutenin subunit Bx17 endosperm-specific promoter; LTB, heat-labile enterotoxin B 
subunit of Escherichia. coli; RAmy3D, rice α-amylase 3D promoter; TOL, TMV Omega-
prime leader, containing transcriptional and translational enhancer from the coat protein 
gene of TMV; TSP, total soluble protein; all yield values are highest levels reported. 
2Total soluble protein levels were not reported in this study. 
3Study also showed antibody production against protein. 
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was effective in inducing systemic and mucosal immune responses in mice. Serum from 
immunized mice inhibited PEDv plaque formation by 49.7% in comparison to controls. 
1.1.3.4 M Protein 
1.1.3.4.1 Structure and Conservation  
M is an N-glycosylated transmembrane protein, and is the most abundant component of 
the viral envelope (Neuman et al., 2011; Utiger et al., 1995). M is predicted to have three 
transmembrane segments, with two flanking domains one short, and one long (The 
UniProt Consortium, 2015). It was experimentally shown that the shorter domain lies 
outside the virion on the amino terminus, and a longer carboxyl tail is found inside the 
virion (Utiger et al., 1995). 
In contrast to S, M is more conserved (Chen et al., 2014; Sato et al., 2011). PEDv was 
propagated through serial passages in Vero cells, and gene sequences were analyzed at 
the 34th, 61st, and 100th passage. Vero cells are a cell line derived from kidney epithelial 
cells from African green monkey of the Chlorocebus genus, and are commonly used for 
viral propogation. The S gene had 6, 10, and 18 nucleotide changes at each respective 
passage, causing 5, 9, and 13 amino acid substitutions respectively, in comparison to the 
original sequence. The amino acid sequence of the M gene was unaffected until the 61st 
passage, after which there was one mutation that changed the amino acid sequence (Sato 
et al., 2011). To ensure that a vaccine candidate is effective against multiple strains, it is 
better to use a protein that is not prone to variation or adaption. A comparison of M and S 
protein sequences of PEDv strains from 16 different pig farms in China, showed that M 
proteins shared 97.8%-100% amino acid identity, while in comparison S proteins showed 
94.6%-100% amino acid identity, and importantly showed amino acid substitutions in the 
neutralizing epitope region (Sun et al., 2014). 
1.1.3.4.2 Antigenicity of M Protein 
In addition to showing strong conservation over serial passages, the coronavirus M 
protein has been shown to induce both humoral and cellular immune responses. The M 
protein of SARS-CoV, a betacoronavirus, has two cytotoxic T-cell epitopes in the second 
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and third transmembrane domain (Liu et al., 2010). The M protein of mouse hepatitis 
virus (MHV), also a betacoronavirus, has CD4+ T-cell epitopes on its carboxyl tail (Xue 
et al., 1995).  
The M protein of SARS-CoV has B-cell epitopes both on the N and C-termini (He et al., 
2005). The C-terminus of avian infectious bronchitis coronavirus (IBV), a 
gammacoronavirus, M protein is also found to have a B-cell epitope (Xing et al., 2009). 
Further, monoclonal antibodies against M of TGEV have virus-neutralizing activity in the 
presence of complement, the part of the immune system that enhances antibody ability to 
clear pathogens (Woods et al., 1988). Recombinant M protein of SARS-CoV also induces 
neutralizing antibodies in the presence of complement. The neutralizing capacity of M 
protein from SARS-CoV was higher or the same when compared to the neutralizing 
capacity of 8 individual S protein fragments (Pang et al., 2004).  
Coronavirus M protein also is able to stimulate interferon-α production, which in turn 
increases major histocompatibility complex (MHC) class I expression, and thus antigen 
presentation in cells (Laude et al., 1992).   
The B-cell epitope of IBV M protein was experimentally determined to be amino acids 
199FATFVYAK206 on the C-terminal tail (Xing et al., 2009). The homologous region on 
the PEDv M protein C-terminus contains the B-cell epitope, amino acids 195WAFYVR200, 
and this epitope is conserved in ten different PEDv strains analyzed. Nine different 
coronaviruses (PEDv, TGEV, canine coronavirus (CCoV), feline coronavirus (FCoV), 
human coronavirus 229E (HCoV 229E), HCoV OC43, MHV, SARS-CoV, turkey 
coronavirus (TCoV), IBV) were compared and three of the five amino acids A196, Y198 
and V199 are conserved among all nine coronaviruses (Zhang et al., 2012). HCoV 229E M 
protein is of interest, as it is the most closely related to PEDv M, with 57% sequence 
identity (Duarte et al., 1994). This further shows the conserved nature of M as useful for 
vaccine design. Future studies may find that PEDv M also contains the B-cell and T-cell 
epitopes found on M of other coronaviruses, especially as monoclonal antibodies were 
shown to bind to the N terminus of PEDv M (Utiger et al., 1995). 
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1.1.3.4.3 Role in Viral Assembly 
Apart from its antigenicity, M is also a useful candidate for vaccine design due to its key 
role in viral assembly, allowing it to be used to produce VLPs. Coronavirus assembly and 
budding takes places in the endoplasmic reticulum-Golgi intermediate compartment 
(ERGIC). M-M interactions drive the formation of the envelope, and M-M associations 
are thought to take place in pre-Golgi compartments  (de Haan et al., 2000), with M 
having been shown to be localized to the trans Golgi, cis-Golgi, or trans Golgi network, 
depending on the coronavirus (reviewed by Ujike and Taguchi, 2015). ER-retained M is 
able to recycle from the Golgi complex to early compartments, potentially to allow M 
proteins that did not assemble into the virion another chance to do so through retrograde 
transport (de Haan et al., 2000).  It is thought that M forms a lattice-like circular matrix 
within the viral envelope with open positions, which S and E proteins can fill through 
specific interactions with M when in the ER and ERGIC membranes (de Haan et al., 
2000; Lim and Liu, 2001). In this process M efficiently excludes foreign proteins 
(Nguyen and Hogue, 1997). The N protein then attaches to the M matrix (de Haan et al., 
2000). M will only bind to N when N is complexed with RNA (Narayanan et al., 2000). It 
is hypothesized that E may be involved in membrane scission to have the virion bud off 
and impact the rearrangement of the organelles of the ER-Golgi complex for virion 
trafficking, but this requires further research, particularly as M-only VLPs have been 
produced (reviewed by Ruch and Machamer, 2012). 
Changes in any part of the M protein, including the amino terminus, transmembrane 
spanning regions, amphipathic domain and carboxyl tail have effects on M assembling 
into enveloped particles (de Haan et al., 1998). Mutations of the M protein are better 
tolerated when M is in the presence of all structural proteins, rather than when M and E 
VLPs are being produced. This is likely because of the stabilization provided by 
interaction with all proteins, particularly the nucleocapsid (de Haan et al., 1998). 
However, the carboxyl terminus is critical for envelope assembly, with truncation of just 
the single terminal residue preventing virion or VLP formation (de Haan et al., 1998). 
The carboxyl tail is involved in Golgi retention, and contains a conserved domain 
important for viral envelope formation, and in mediating M-M interactions during viral 
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assembly, though other domains, especially the transmembrane domains, are also 
important (Arndt et al., 2010; de Haan et al., 2000) . The carboxyl tail may also be 
important in M-N interactions, allowing N to potentially stabilize M complexes (Arndt et 
al., 2010).  
1.1.3.4.4 M is Crucial for VLP Formation 
The minimum requirements for coronavirus-like particle formation have been 
controversial, and vary depending on the virus. It was previously thought that M and E 
were the minimal requirements to form VLPs, as shown with MHV, where it was also 
observed that glycosylation of M makes no difference on viral assembly (de Haan et al., 
1998). However, conflicting studies have emerged for SARS-CoV. An initial study found 
M and E were sufficient for VLP formation (Ho et al., 2004), aligning with previous 
coronavirus research, but a subsequent study instead found that M and N were both 
sufficient and necessary to form VLPs (Huang et al., 2004). Another study has shown 
that SARS CoVLPs can be produced with only M, or M and N (Tseng et al., 2010). 
Further, VLPs for IBV were produced by co-expressing M and S (Liu et al., 2013). The 
requirements to produce PEDv VLPs are not known, as they have never been reported in 
the literature.  
1.1.3.4.5 Previous Recombinant Expression 
As a membrane protein, M can be difficult to express. Some groups have attempted to 
express full length PEDv M in E. coli only to resort to expressing different fragments of 
the protein (Zhang et al., 2012), or just expressing a truncated version of the protein 
(Shenyang et al., 2007). Recombinant expression of M has mostly utilized prokaryotic 
platforms, and M is almost always expressed as a fusion protein. Two groups have 
produced M in eukaryotic platforms (Ren et al., 2012; Utiger et al., 1995). While some of 
the produced M proteins have induced antibodies, none of these antibodies have been 
tested for virus neutralizing activity. Table 2 lists all known studies that have produced 
recombinant PEDv M protein. 
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Table 2. List of all work on recombinant expression of PEDv M protein. 
Full Length? Modifications Host Species1 Induces 
antibodies? 
Reference 
Carboxyl tail N-terminal 
Glutathione s-
transferase (GST) 
tag, C-terminal 
His6 tag 
E. coli Yes (Zhang et al., 
2012) 
N terminus N-terminal GST E. coli Yes (Shenyang et 
al., 2007) 
Signal peptide 
deletions 
- E. coli Yes 
 
(Ren et al., 
2011) 
Full length N-terminal GST E. coli N/A (Fan et al., 
2015) 
Full length N-terminal maltose 
binding protein 
(MBP), C-terminal 
cellulose-binding 
domain (CBD) 
E. coli N/A (Zhang et al., 
2011) 
Full length None, or fusion 
with N 
Salmonella 
choleraesuis, 
Vero cells 
Yes: S. 
choleraesuis as a 
DNA vaccine, 
with M-N fusion 
(Ren et al., 
2012) 
Full length - Sf9 cellsa, Vero 
cellsb 
Yes (Utiger et al., 
1995) 
1Sf9 cells, insect cells from the ovarian tissue of Spodoptera frugiperda; Vero cells, 
kidney epithelial cells from an African green monkey of the Chlorocebus genus.  
18 
  
No reports to date show expression of PEDv M, or any full length PEDv protein, in 
plants. Three reasons may be behind this: first, M can be difficult to express, second, 
membrane proteins in general present difficulties (discussed below), and third, that S 
COE has been the focus of vaccine design, with the B-cell epitope of M only having been 
identified in 2012 (Zhang et al., 2012). 
1.2 Membrane Protein Expression and Extraction 
Recombinant production of eukaryotic membrane proteins in heterologous expression 
systems can be a difficult task (Grisshammer, 2006). Membrane protein synthesis most 
commonly requires the polypeptide to be targeted to a protein-conducting channel 
(translocon) in the ER, to then be released into the ER membrane where it folds into its 
correct conformation. Only proteins that are correctly folded pass into the Golgi, 
otherwise proteins are degraded (reviewed by Grisshammer, 2006). The detection of 
incorrectly folded proteins triggers the unfolded protein response (UPR), which either 
targets these proteins for degradation, or causes cell apoptosis, in both mammalian and 
plant cells (Iwata and Koizumi, 2005). In addition, the use of strong promoters resulting 
in a large number of mRNAs which are translated on ribosomes and inserted into the ER 
may overwhelm the ER protein folding machinery, leading to increased misfolding and 
UPR. This may result in reduced accumulation of membrane proteins. To confound 
matters further, not all membrane proteins elicit UPR (Grisshammer, 2006). Why some 
membrane proteins insert and fold better than others is not understood. The ER 
translocon recognizes transmembrane helices, inserting them into the membrane rather 
than allowing the helices to pass into the aqueous compartment, and arranging the 
orientation of the newly synthesized protein. This topology outcome is driven by 
synthesis rate as well as the length of the hydrophobic segment, and the positioning of 
key charged residues in the translocon, which can inform orientation of the protein. 
However, these residues are not conserved in all translocons, leading to difficulties and 
trial and error in heterologous membrane protein expression (reviewed by Bowie, 2005). 
As some proteins may require post-translational modifications that only some eukaryotic 
cell lines have the machinery for, it can be necessary to test various expression systems 
for each protein (reviewed by Junge et al., 2008). 
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Aside from expression, membrane proteins are difficult to study due to their hydrophobic 
surfaces and unstable nature. This is problematic as 20-30% of most proteomes (Krogh et 
al., 2001), and 60% of drug targets (Overington et al., 2006) are membrane proteins 
(Carpenter et al., 2008). Despite this, of the 121, 654 proteins whose structure has been 
identified and deposited in the Protein Data Bank, only 2, 829 are identified as membrane 
proteins (Kozma et al., 2013). A difficult component of studying membrane proteins is 
their extraction. Membrane protein extraction is reliant on the use of detergents, where 
often a series of detergents needs to be tested to see which extracts the highest amount of 
a particular protein (Carpenter et al., 2008).  
1.2.1 Importance of Detergents  
1.2.1.1 Detergent Properties  
Membrane proteins are by definition, at least partially embedded in membranes. 
Biological membranes are typically amphiphilic lipid bilayers (Arnold and Linke, 2008). 
Detergents have properties to mimic the lipid environment which helps to solubilize 
membranes, allowing for stable extraction of membrane proteins, or membrane protein 
complexes. Detergents are amphiphilic, with a hydrophilic headgroup and a hydrophobic 
section, normally made up of an extended hydrocarbon chain (Arnold and Linke, 2008). 
Detergents allow membrane protein extraction by partitioning into lipid bilayers, where 
cooperative detergent-detergent interactions destabilize the bilayer to give mixed lipid-
detergent fragments. More detergent then leads to the dissolution of the bilayer and 
protein solubilisation (reviewed by le Maire et al., 2000). The final result is that the 
transmembrane domains of the proteins are covered by a torus of detergent molecules 
(reviewed by Garavito and Ferguson-Miller, 2001). 
1.2.1.2 Detergent Types 
Four classifications of detergents exist, based on the electrical charge of the hydrophilic 
group: non-ionic, zwitterionic, anionic, and cationic. The properties of the detergents 
within these categories depends on the structure and size of the polar headgroup, and 
length of the attached hydrocarbon chain (Arnold and Linke, 2008). Detergents have the 
ability to denature proteins. Ionic detergents in particular are harsh on proteins, as they 
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have the ability to disrupt both inter- and intra-molecular protein interactions. Thus ionic 
detergents are not typically used for procedures requiring protein stability. Non-ionic 
detergents are better suited for keeping proteins active and not affecting structural 
features (le Maire et al., 2000). Some membrane proteins are not active in pure 
detergents, therefore it can be undesirable to wash off most of the membrane lipids with 
too high of a detergent concentration. Solubilisation, and the concentration at which 
delipidation occurs, depends on detergent choice, the protein, and medium conditions in 
the buffer (le Maire et al., 2000).  
There are multiple kinds of non-ionic detergents, which as a group are characterized by 
having an uncharged hydrophilic headgroup. One family is the tert-Octylphenol 
poly(ethyleneglycolether)n detergents, which includes the Triton, Nonidet, and Igepal 
detergents. These have a poly(ethyleneglycol) (PEG) headgroup, and a tert-octyl chain. 
Detergents in this family are mild, and rarely denature membrane proteins (Arnold and 
Linke, 2008). Detergents in this family typically have slight differences in the average 
size n and size distribution of their headgroups. Triton X-114 has been frequently used 
for phase separation due to its cloud point of 22ºC. Triton X-100 can also be used for 
phase separation, as its cloud point can be brought down with the addition of PEG, 
dextran, glycerol, NaCl or (NH4)2SO4 (Arnold and Linke, 2008).  
There are other groups of non-ionic detergents. One is polyoxyethylene sorbitan esters of 
fatty acids, commonly known as Tween. These are also mild detergents. Tween 
detergents are mixtures of complex polymers (Ayorinde et al., 2000). Another is 
polyoxyethylene glycol monoether detergents. These are named CxEy for their alkyl chain 
length and number of polyoxyethylene glycol units in the headgroup respectively (Arnold 
and Linke, 2008). These typically go by trade names, for example C12E23 goes by Brij 35.  
Anionic detergents are those such as sodium dodecyl sulfate (SDS). These are harsh 
detergents with small headgroups that denature most proteins (Arnold and Linke, 2008). 
This detergent is primarily used for SDS-PAGE. This technique relies on full 
denaturation of proteins using SDS and heat followed by electrophoretic separation of 
proteins in a matrix such as polyacrylamide to assess molecular weight. Some membrane 
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proteins are resistant to SDS denaturation, and also have heat modifiability – where 
apparent molecular weight changes depending on whether the samples with SDS in them 
are heated before separation by SDS-PAGE. SDS is also known to precipitate at low 
temperatures (Arnold and Linke, 2008). Cationic detergents also typically denature 
proteins, though some proteins remain fully functional (Arnold and Linke, 2008). CTAB 
is an example of a cationic detergent. 
1.3 Hypothesis and Objectives 
I hypothesize that using N. benthamiana as a bioreactor, the full length M protein of 
PEDv will be transiently produced and extracted, and VLPs for PEDv can be formed 
either with M alone, or in conjunction with E, S, or N. 
The specific objectives of this study were: 
1. Design and identify which gene constructs will lead to the highest transient 
expression levels of PEDv M in N. benthamiana. 
2. Transiently express gene constructs and determine which detergents are most 
efficient for extracting PEDv M. 
3. Investigate the capacity of plants to produce virus-like particles with the M 
protein, or with M in combination with E, S, or N. 
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2 Materials and Methods 
2.1 Gene Synthesis 
Peptide sequences for the membrane, spike, nucleocapsid and envelope proteins were 
obtained from the National Center for Biotechnology Information (NCBI) database 
(accession number KF650373). This sequence is from a PEDv strain isolated in the U.S. 
that showed ≥99.7% nucleotide identity with nine other U.S. strains that have been 
sequenced (Chen et al., 2014). The M, N, and E nucleotide sequences were synthesized 
by BioBasic Inc. (Markham, Ontario), optimized for nuclear expression in N. tabacum 
with a C-terminal fusion to a StrepII tag (Schmidt et al., 1996) for protein purification. 
The gene sequence is flanked with attL sites for Gateway® recombination (Hartley et al., 
2000) into transient expression vectors, or attB sites for Gateway® recombination into 
entry vectors. The S nucleotide sequence was synthesized by GenScript (Piscataway, 
U.S.A), optimized for nuclear expression in N. tabacum, flanked by attL sites and 
contained a C-terminal fusion to a StrepII tag. 
2.2 Transient Assays 
2.2.1 Composition of Cloning and Infiltration Reagents 
The composition of the buffers used for cloning and agroinfiltration is detailed in Table 
3. 
2.2.2 Gateway Cloning® 
Gateway® cloning technology (Invitrogen, Thermo Fisher Scientific, Waltham, U.S.A.) 
was used to recombine M, N, and E gene cassettes into pCaMGate expression vectors 
(Pereira et al., 2014). Gene constructs that were synthesized with flanking attB sites 
underwent a BP reaction to be cloned into the pDONR vector. This was followed by an 
LR reaction to introduce the inserts into various expression vectors. For the BP 
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Table 3.  Recipes for cloning and infiltration reagents 
Reagent Recipe 
Lysogeny broth (LB), Miller 10 g tryptone, 5 g yeast extract, 10 g NaCl 
in 1 L Milli-Q water 
LB agarose LB + 1.5% agar  
LB/LB agarose with kanamycin LB/LB agarose with50 μg/μl kanamycin 
LB agarose with kanamycin and rifampicin LB/LB agarose with50 μg/μl kanamycin 
and 10 μg/μl rifampicin 
Infiltration medium 10 mM 2-(N-morpholino)ethanesulfonic 
acid (MES) at pH 5.6, 100 μM 
acetosyringone, 50 μg/ml kanamycin, and 
10 μg/ml rifampicin in LB 
Gamborg’s solution 3.2 g/L Gamborg’s B5 with vitamins, 20 
g/L sucrose, 10 mM MES (pH 5.6), 200 
μM acetosyringone 
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reaction, 100 ng of the pUC57 vector containing the different genes of interest (GOI) was 
recombined with 300 ng of pDONR using 1 μl of BP Clonase® enzyme mix (Invitrogen) 
overnight at room temperature. After transformation into E. coli, (described in 2.2.4), and 
plasmid extraction (described in 2.2.4), the recombined plasmid underwent the LR 
reaction. 100 ng of pDONR with GOI were recombined into 300 ng of expression vector 
using 1 μl of LR Clonase® enzyme mix (Invitrogen) overnight at room temperature. 
2.2.3 Golden Gate Cloning 
Golden Gate cloning (Engler et al., 2008) was used to recombine the S gene construct 
into the elastin-like polypeptide-endoplasmic reticulum (ELP-ER) pCamGate expression 
vector (Pereira et al., 2014).  In a microcentrifuge tube 200 ng of expression vector and 
pUC57 plasmid containing the GOI, 2 μl of CutSmart buffer (New England Biolabs, 
Whitby, Canada) supplemented with 10 mM adenosine triphosphate (ATP), 18 μl of 
Milli-Q water, and 1 μl of both BsaI (New England Biolabs) and T4 DNA Ligase (New 
England Biolabs) were mixed. The reaction was incubated for 1 hour at 37 °C. 
2.2.4 E. coli Transformation 
pCaMgate expression vectors with GOIs were transformed in to E. coli XL1-Blue, using 
the Gene Pulser II system (Bio-Rad Laboratories Inc, Hercules, U.S.A.) 1.5 μl of BP or 
LR reaction, or 2 μl of Golden Gate reaction was added to 40 μl of E. coli which were 
then electroporated. Cells were then immediately diluted with 960 ml of LB, incubated 
for 1 hour at 37°C at 250 rpm (Innova® 42 Incubator, Eppendorf, Hamburg, Germany), 
and 20 and 200 μl aliquots were plated on LB agarose plates with kanamycin. Plates were 
incubated overnight at 37°C.  
Colonies were screened using polymerase chain reaction (PCR) with gene-specific 
primers to select for colonies with the GOI. Colonies that were found to be positive were 
used to inoculate 5 mL of LB with kanamycin and grown at 37°C at 250 rpm overnight. 
Plasmid DNA was extracted using the QIAprep® Spin Miniprep Kit (Qiagen, Venlo, 
Netherlands) following manufacturer’s protocols. Extracted plasmid DNA was screened 
using PCR.  
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2.2.5 Agrobacterium tumefaciens Transformation 
Electro-competent A. tumefaciens EHA 105 cells were transformed like E. coli, except 
incubated at 28°C at 250 rpm for one hour, and plated on LB agarose plates with 
kanamycin and rifampicin, then incubated for two days at 28°C. 
2.2.6 Transient Expression in Nicotiana benthamiana 
Transformed A. tumefaciens colonies, with expression constructs with either GOI or p19, 
were used to inoculate 3 ml of LB with kanamycin and rifampicin. Cultures were 
incubated from 1PM to the following morning at 28°C at 250 rpm. These cultures were 
used to inoculate 50 ml of infiltration medium. A 1/4000 dilution of A. tumefaciens that 
contained the GOI expression vectors, and 1/2000 dilution of A. tumefaciens containing 
p19 was used to inoculate infiltration medium. The inoculated infiltration culture was 
incubated overnight at 28°C at 250 rpm until an optical density at 600 nm (OD600) of 0.5-
1.0 was reached, measured with a Nanodrop 2000c spectrophotometer (Thermo Fisher 
Scientific). Cultures were then centrifuged at 6000 x g for 10 minutes, and resuspended in 
Gamborg’s solution to an OD600 of 1.0. Cultures were then incubated at room 
temperature with gentle agitation for at least 1 hour. A. tumefaciens cultures containing 
GOI expression constructs were mixed with an equal volume of A. tumefaciens cultures 
containing the p19 expression vector. This was sometimes then diluted with an equal 
volume of Gamborg’s solution, giving an A. tumefaciens OD600 of either 0.5 or 0.34 for 
each culture. If multiple GOI were being co-expressed, they were all mixed in equal 
volumes without Gamborg’s solution, such that the final OD600 of each culture was 0.34, 
0.25, or 0.2, for co-expression of 2, 3, or 4 cultures with GOI expression constructs, 
respectively.  
These cultures were used to infiltrate 5-7 week old N. benthamiana plants that were 
grown in a growth room with the following conditions: 16 hours of light/8 hours of dark, 
21-22°C, 55% humidity, and receiving approximately 100 μmol/photons m-2s-1 of 
photosynthetically active radiation (PAR). If syringe infiltrations were performed, a 3 ml 
syringe was used to infiltrate the A. tumefaciens suspensions into the underside of the 
leaves, occasionally with the help of a needle to make a cut. Three different biological 
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replicates were used, with constructs having equal representation on the lower, middle, 
and upper leaves of the plants. After infiltration, plants were returned to the growth 
chamber until tissue was collected two to eight days later.  
If vacuum infiltrations were performed, the soil of the pot was covered with a plastic 
film, and the plant was inverted into a 1L beaker containing a mixture of Gamborg’s 
solution and A. tumefaciens containing expression constructs for GOI and p19. The pot 
was supported by two metal slats sitting on top of the beaker. The beaker was placed in a 
sealed chamber. The connected VPD3 pump (VIOT, Champagne, U.S.) was turned on 
until a vacuum of 25” mercury was reached. The valve connecting the pump and chamber 
was then closed, and the chamber was held at 25” mercury for 1 minute to allow air in the 
interstitial spaces of N. benthamiana leaves to escape. The vacuum was then released 
over 30 seconds to allow A. tumefaciens culture to enter the interstitial spaces.  
2.2.7 Small Scale Tissue Collection and Protein Extraction  
To collect tissue, a 7.1mm diameter cork borer was used to collect three leaf discs from 
each infiltrated leaf. For pooled samples, one disc was taken from the infiltrated leaf of 
each biological replicate. Tissue was collected in 2 ml microcentrifuge tubes containing 
three 2.3 mm ceramic beads. Tissue mass was measured using a Sartorius (Göttingen, 
Germany) B 120S fine balance, and the tissue was then flash frozen in liquid nitrogen, 
and subsequently stored at -80°C until extraction. 
To extract protein, microcentrifuge tubes containing tissue were placed in 
homogenization blocks that had been pre-cooled to -80°C. Tissue was homogenized 
twice for 1 minute at 30 hertz in a TissueLyser (Qiagen). Blocks were then centrifuged 
for 1 minute at 2254 x g.  
Various extraction buffers were used, and details are given in Table 4.  
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Table 4. Composition of various buffers used for protein extraction1,2.  
Extraction 
Buffer 
Detergent Protease Inhibitors Buffer 
Plant 
Extraction 
Buffer (PEB) 
0.1% (v/v) Tween-20 2% (PVPP) (w/v), 1 
mM EDTA, 1 mM 
PMSF, 1 µg/ml 
leupeptin, 100 mM 
sodium L-abscorbate 
1xPBS, 
pH 7.8 
Detergent 
Screen Buffer 
(DSB) 
1% (v/v) sodium dodecyl 
sulfate (SDS),  
1% (v/v) Brij L23,  
1% (v/v) Triton X-100,  
1% (v/v) Tween-20,  
7 M urea/2 M thiourea/4% 
(w/v) CHAPS,  
or no detergent 
2% PVPP, 1 mM 
EDTA, 1 mM PMSF, 1 
mg/ml leupeptin, 100 
mM sodium L-
abscorbate 
100 mM 
Tris pH 
7.5-8 
ProteoExtract® 
Native 
Membrane 
Protein 
Extraction Kit3 
0.2% digitonin (Buffer 1) 
0.5% Triton X-100 (Buffer 2) 
Protease Inhibitor 
Cocktail (Calbiochem 
539134; 100 mM 
AEBSF, 80 µM 
aprotinin, 5 mM 
bestatin, 1.5 mM E-64, 
2 mM leupeptin, 1 mM 
pepstatin A, in DMSO) 
300 mM 
Saccharose 
15 mM 
NaCl 
10 mM 
Pipes pH 
7.2 
Final Lab 
Extraction 
Buffer (FEB) 
1.5% (v/v) Triton X-100 2% PVPP, 1 mM 
EDTA, 1 mM PMSF, 1 
mg/ml leupeptin, 100 
mM sodium L-
abscorbate 
100 mM 
Tris pH 8, 
300 mM 
sucrose, 15 
mM NaCl 
VLP 
Extraction 
Buffer (VEB) 
0.1% Triton X-100 2% PVPP, 1 mM 
EDTA, 100 mM sodium 
L-abscorbate 
50 mM 
Tris-HCl 
pH 7.5 
140 mM 
NaCl 
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1Initial extractions were performed with Plant Extraction Buffer (PEB), extraction 
optimization was performed with the Detergent Screen Buffers, as well as with the 
ProteoExtract® Native Membrane Protein Extraction Kit, the optimized extraction buffer 
was Final Extraction Buffer, and the VLP Extraction Buffer was used for VLP analysis. 
2 AEBSF, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride ; CHAPS, 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate; DMSO, dimethyl sulfoxide; 
EDTA, ethylenediaminetetraccetic acid; PMSF, phenylmethanesulfonylfluoride. 
3The ProteExtract® Native Membrane Protein Extraction Kit contained two buffers for 
sequential extraction of soluble proteins (Buffer 1), then membrane proteins (Buffer 2). 
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Two extraction methods were used – one for lab made buffers, and one for the 
commercial kit. When using lab made buffers, after homogenization blocks were 
centrifuged, 200 µl of buffer was added to each microcentrifuge tube. Microcentrifuge 
tubes were mixed for three seconds on a vortex mixer, inverted and mixed for another 
three seconds. Microcentrifuge tubes were centrifuged at 4ºC for 15 minutes at 17,949 x 
g. The supernatant from each microcentrifuge tube was collected into a 1.5 ml 
microcentrifuge tube and then centrifuged again for 15 minutes at 4ºC. Extract was mixed 
in a 4:1 ratio with a sample buffer containing 0.3 M Tris-HCl pH 8.0, 5% (w/v) SDS, 
10% (v/v) glycerol, 100 mM dithiothreitol (DTT) and 0.05% (w/v) phenol Red. Extracts 
were then run on SDS-PAGE gels or stored at -80ºC.  
If the ProteoExtract® Native Membrane Protein Extraction Kit was used, the 
manufacturer’s protocol was followed. After centrifugation of homogenization blocks, 
5 µl of the kit’s Protease Inhibitor Cocktail and 0.5 ml of Buffer 1 were added to each 
microcentrifuge tube. Microcentrifuge tubes were mixed by two 3 second pulses on a 
vortex mixer. Microcentrifuge tubes were then incubated for ten minutes at 4ºC with 
gentle agitation using a rotary shaker. All microcentrifuge tubes were then centrifuged at 
16,000 x g at 4ºC for 15 minutes. The resulting supernatant from each microcentrifuge 
tube was mixed with sample buffer as described for lab-made buffer protein extract, and 
labelled the soluble fraction. The pellet was resuspended in 2.5 µl Protease Inhibitor 
Cocktail and 0.5 ml Buffer 2 using a pipette. The suspension was incubated for 30 
minutes at 4ºC with gentle agitation using a rotary shaker, then centrifuged at 16,000 x g 
at 4ºC for 15 minutes. The supernatant was mixed with sample buffer as described for 
lab-made buffer protein extract.  
2.2.8 Large Scale Tissue Collection and Protein Extraction and 
Concentration for VLP Detection 
Infiltrated leaves were collected and placed in plastic bags, in 8 gram portions. The tissue 
was then immediately stored at -80ºC until it was extracted. 
To extract protein, leaf tissue was placed in a large mortar, mixed with liquid nitrogen 
and ground into a fine powder with a pestle. Three parts (v/w) extraction buffer were 
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added to the mortar, and the mixture was ground in to a paste. Using a serological pipette 
the solution was then transferred to a conical tube. The solution was centrifuged twice for 
ten minutes at 4,200 x g. To concentrate any produced VLPs, 22 ml of supernatant was 
applied to a discontinuous sucrose gradient ranging from 30% to 60% in 10% 3 ml steps. 
The gradient was then ultracentrifuged using an Optima™ L-100 (Beckman Coulter) and 
a SW28 rotor at 86,329 x g at 4ºC. Ultracentrifuge ubes had a hole pierced in the bottom 
through which each fraction was collected and stored on ice at 4ºC, or stored at -80ºC 
until analyzed.  
2.2.9 Western Blotting Procedure 
Protein extracts were analyzed by immunoblot to determine protein accumulation, and 
the reagents used are detailed in Table 5. Other than where noted, samples were not 
boiled. 20 to 40 µl of sample were loaded onto Bio-Rad Mini-Protean® TGX™ Precast 
4-20% (w/v) polyacrylamide gradient gels, except where noted. Gels were run at 115 V 
to start, then voltage was increased up to 140 V. Gels were run until dye reached the 
bottom of the gels. Proteins were transferred from gel to polyvinylidene difluoride 
(PVDF) membranes (Bio-Rad Laboratories, Inc.) using a Bio-Rad Trans-Blot® Semi-
Dry Transfer Cell apparatus at 25 V and the membranes were blocked overnight in 
blocking solution.  
To verify the detected protein was not a plant peroxidase, membranes were washed with 
TBS-T for 10 minutes, ECL Prime Western Blotting Detection Reagent (GE Healthcare 
Life Sciences, Little Chalfont, UK) was incubated with the membrane for 1 minute, and 
proteins were then visualized in a MicroChemi 4.2 (DNR Bio-Imaging Systems, 
Jerusalem, Israel). Membranes were then washed twice for ten minutes in TBS-T.  
Membranes were then hybridized with primary antibody solution for one hour, under 
gentle agitation. Membranes were washed 3 x 15 minutes in TBS-T, then hybridized for 
one hour with secondary antibody solution. Three more TBS-T washes were performed 
under gentle agitation for 10 minutes each. Membranes were then rinsed in 1xTBS, after 
which ECL Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences,   
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Table 5. Reagents used for Western blotting procedures. 
Reagent Recipe 
10x Tris-buffered saline (TBS) 20 mM Tris, 300 mM NaCl, pH 7.5 
1x TBS 10x TBS diluted to 1x with Milli-Q water 
TBS-T 1x TBS with 0.1% Tween-20 
Blocking solution 5% (w/v) skim milk powder in TBS-T 
Primary antibody solution 1:4000 dilution of monoclonal mouse anti-
c-Myc primary antibody (GenScript) in 
0.5% (w/v) skim milk powder in TBS-T 
Secondary antibody solution 1:4000 polyclonal goat anti-mouse 
secondary antibody (Bio-Rad Laboratories, 
Inc.) conjugated to horseradish peroxidase 
in 0.5% (w/v) skim milk powder in TBS-T 
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Little Chalfont, UK) was incubated with the membrane for 1 minute. Proteins were then 
visualized in a MicroChemi 4.2 (DNR Bio-Imaging Systems, Jerusalem, Israel). 
2.3 Protein Quantification 
Total recombinant protein was quantified through the use of dot blots. Sample extracts 
and negative controls from the same biological replicates were spotted on to 
nitrocellulose membranes (Bio-Rad Laboratories, Inc.) in a dilution series. Known 
amounts of a cellulose binding domain (CBD) synthetic protein standard (GenScript) 
were also spotted in two sets of dilutions for densitometry analysis. Membranes were 
allowed to dry for forty five minutes, and then blocked overnight in blocking solution. 
Membranes were processed as described in 2.2.9 for the Western blotting procedure. 
Recombinant protein was quantified using Totallab TL100 software (Nonlinear 
Dynamics, Durham, USA). Two sets of CBD dilutions were used to develop a standard 
curve which was used to determine the amount of protein in samples. The amount of 
protein in mg per g was then calculated using the tissue weight of each sample. Final 
accumulation amount was determined by subtracting any detected protein in negative 
control dilutions from the amount of protein detected in sample dilutions. A balanced 
analysis of variance (ANOVA), followed by Tukey Pairwise Comparisons was 
performed with Minitab (State College, Pennsylvania, USA) to analyze differences in 
mean accumulation levels. Statistical significance level for all the tests was defined as 
0.05 or lower. 
2.4 VLP Analysis 
2.4.1 Transmission Electron Microscopy  
To assess whether VLPs were formed, large scale infiltrations were performed, and 
protein extracted and concentrated, as described above, using the VLP extraction buffer 
(Table 4). Analysis of sucrose gradient fractions for VLP formation was performed using 
transmission electron microscopy (TEM). A droplet of extract was placed on carbon grids 
(Electron Microscopy Sciences, Hartfield, U.S.), and allowed to sit for two minutes. 
Liquid was then drawn off, and the grid was washed in three consecutive drops of water 
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for two minutes each. Finally, a drop of 2% uranyl acetate was placed on the grid, and 
allowed to sit for a minute before being drawn off. The negatively stained grids were 
examined with a CM-10 transmission electron microscope (Philips, Amsterdam, 
Netherlands) equipped with a digital camera (Advanced Microscopy Techniques, MA) at 
80 kV. 
2.4.2 TEM Immunogold Labeling  
A droplet of protein extract from the 40% sucrose fraction of either M-ELP, co-expressed 
M-ELP and E-ELP, or wild type tissue was placed on a carbon grid (Electron Microscopy 
Sciences), and allowed to sit for two minutes. Liquid was then drawn off. Grids were 
blocked by placing them specimen-side down in a drop of goat normal serum (25596; 
Aurion, Netherlands) for fifty minutes. Grids were washed in two consecutive drops of 
dilution buffer (1% bovine serum albumin (BSA), 0.2% BSA-c™ (Aurion), 0.05% 
Tween-20 in PBS pH 7.35) for two minutes each. One set of grids was incubated 
specimen-side down in a droplet of mouse anti-c-Myc primary antibody diluted 1:10 with 
dilution buffer , while a second set of grids was simultaneously incubated with just 
dilution buffer as a negative control. All grids were then washed in three consecutive 
drops of dilution buffer for two minutes. All grids were incubated for one hour in a drop 
of secondary antibody diluted 1:10 in dilution buffer. Secondary antibody was goat anti-
mouse IgG conjugated to 10 nm gold particles (Aurion). Grids were washed in three 
consecutive drops of dilution buffer for ten minutes each, and then in four consecutive 
drops of Milli-Q water for three minutes each. Once dry, grids were stained with 2% 
uranyl acetate and examined under TEM as in 2.4.1.  
2.5 Mass Spectrometry 
The reagents used for mass spectrometry are described in Table 6. Protein extracts were 
run on an SDS-PAGE gradient gel as described in 2.2.9. The gel was incubated in gel 
fixing solution for fifteen minutes. The gel was subsequently washed with Milli-Q water 
3 x 5 minutes each. 20 ml of GelCode™ Blue Stain Reagent (Thermo Fisher Scientific) 
was applied to the gel, which was then incubated for two hours. The gel was then  
  
34 
  
Table 6. Reagents used for mass spectrometry methods. 
Reagents Recipe 
Gel fixing solution 50% methanol, 7% acetic acid in Milli-Q 
water 
Gel destaining solution 50% methanol, 1% acetic acid in Milli-Q 
water 
Destaining solution 80 mg of ammonium bicarbonate, 20 ml of 
acetonitrile, 20 ml of Milli-Q water 
Digestion buffer 10 mg of ammonium bicarbonate with 5 ml 
of Milli-Q water 
Reducing buffer 3.3 µl tris(2-carboxyethyl)phosphine with 
30 µl digestion buffer 
Alkylation buffer 50 mM iodoacetamide in digestion buffer 
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incubated in gel destaining solution 2 x 5 minutes before rinsing in Milli-Q water 
overnight. Bands of interest were then cut out of the gel and stored at -80ºC. 
To digest proteins in the gel, gel pieces were thawed, 200 µl of destaining solution was 
added to each gel piece, and samples were incubated at 37ºC for 30 minutes, after which 
the destaining solution was discarded. This was repeated twice. Samples were then 
reduced by incubating in reducing buffer at 60ºC for ten minutes. Samples were allowed 
to cool, and reducing buffer was discarded. Samples were incubated in 30 µl of alkylation 
buffer in the dark for one hour. Alyklation buffer was then discarded, and samples were 
washed by incubating them in 200 µl of destaining buffer for fifteen minutes at 37ºC with 
shaking. Destaining buffer was discarded, and samples were washed again. Gel pieces 
were shrunk through incubation with 50 µl of acetonitrile for fifteen minutes. Gel pieces 
were air-dried for ten minutes, and incubated with 10 µl of activated trypsin for fifteen 
minutes. 25 µl of digestion buffer was added, and samples were incubated at 30ºC 
overnight with shaking. Digestion mixtures with peptides were then placed in clean 
microcentrifuge tubes.  
These peptide digests were then analyzed in the chemistry facility of the London 
Research and Development Centre of Agriculture and Agri-Food Canada by Dr. Justin 
Renaud using the Easy-nLC 100 nano system at 75 µm x 15 cm Acclaim C18 PepMap™ 
column (Thermo Fisher Scientific) coupled to a Q-Exactive Orbitrap mass spectrometer 
(Thermo Fisher Scientific) and the following protocol. The flow rate used was 300 nL 
min-1 and 10 µl of the protein digest was injected. Equilibration of the C18 was 
performed with 98% mobile phase A (water 0.1% formic acid) and 2% mobile phase B 
(acetonitrile 0.1% formic acid) and elution with a linear gradient from 2-30% B over 
18 minutes followed by 30-98% over 2 minutes and maintained for 10 minutes. 
Nanospray voltage was set at 1.95 kV, capillary temperature 275°C, and S-lens RF level 
60. Q-Exactive was operated in top 10 data-dependent acquisition mode with a full scan 
mass range of 300-1500 m/z at 70,000 resolution, automatic gain control (AGC) of 
1x 106 and maximum injection time (IT) of 250 ms. The MS/MS scans were acquired at 
17,500 resolution, AGC of 1x 106, maximum ITof 110 ms, intensity threshold of 8 x 104, 
normalized collision energy of 27 and isolation window of 1.2 m/z. Unassigned, singly 
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and >4 charged peptides were not selected for MS/MS and a 20 s dynamic exclusion was 
used. The Thermo .raw files were converted to .mgf using Proteowizard v2 (Kessner et 
al., 2008).  
MS/MS scans were then searched against the target/reverse proteome from Sol Genomics 
Network (Bombarely et al., 2012) and the amino acid sequences of the four recombinant 
PEDv proteins using X! Tandem (Craig and Beavis, 2004) search algorithm operated 
from the SearchGUI v2.8.6 (Vaudel et al., 2011) interface and processed in 
PeptideShaker v1.12.2 (Vaudel et al., 2015). An 8 ppm precursor ion mass error and a 
0.05 Da product ion error were used along with carbamidomethylation as a constant 
modification and oxidation of methionine as a variable modification. A 1% false 
discovery rate was used at the protein, peptide, and peptide spectrum match level. 
2.6 In Silico Sequence Analysis 
2.6.1 Protein Structure Analysis 
M and E peptide sequences obtained from NCBI, and the peptide sequences for the M-
ELP and E-ELP fusion proteins were submitted to the I-TASSER server for protein 
structure prediction (Zhang, 2008). The sequence-based predictions of secondary 
structure given by PSSpred algorithm were compared to determine structural similarity 
between proteins.  
2.6.2 VLP Structure Analysis 
The pixel count of TEM scale bars were measured to deduce the nm:pixel ratio for each 
image. The pixel count of VLP envelope thickness was measured in three areas for each 
VLP, and the measurements for all VLPs were averaged. This average was multiplied by 
the nm:pixel ratio to obtain an estimate of VLP envelope thickness.  
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3 Results 
3.1 Transient Expression of M 
3.1.1 Optimal Construct Choice 
The first objective of this study was to determine which M constructs would lead to the 
highest expression levels when transiently infiltrated into leaves of N. benthamiana. The 
PEDv gene sequence used was from strain ISU13-22038 isolated in 2013 (Chen et al., 
2014). Sequence optimization has led to significantly change levels of PEDv protein 
accumulation in plants (Kang et al., 2005a), so the M gene sequence was optimized for 
expression in the nuclear genome of N. tabacum. The gene was cloned into four 
constructs (Figure 3) distinguished by the subcellular targeting signals and fusion 
peptides they contained. The recombinant protein was targeted to either the ER or 
apoplast (Apo). The ER targeted protein was fused either to an ELP or hydrophobin 
(HFBI) tag to potentially increase protein accumulation (Conley et al., 2009a; Joensuu et 
al., 2010), and had a C-terminal KDEL peptide to retrieve it to the ER. A. tumefaciens 
cultures carrying GOI expression constructs were co-infiltrated into N. benthamiana 
leaves with A. tumefaciens carrying a p19 expression construct, a suppressor of gene 
silencing (Silhavy et al., 2002).  
Samples were collected from plant leaves four days post infiltration (DPI). Total soluble 
protein (TSP) was then extracted with PEB (Table 4), and separated on 12% SDS-PAGE 
gels, and analyzed by Western blotting to detect the recombinant protein. Samples were 
collected from three different biological replicates consisting of different plants. Figure 4 
shows that only the ELP-ER cassette resulted in accumulation of M protein. 
Previous literature indicated that the M protein of SARS-CoV showed thermal 
aggregation when heated in Laemmli buffer, resulting in protein being trapped at the 
stacking/separating gel interface (Lee et al., 2005). Thus both the stacking and separating 
gel were transferred to PVDF membrane. No noteworthy amount of M was detected at 
the gel interface (Figure 4). Instead, it is possible that the protein is trapped in the   
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Figure 3. Schematics of the gene constructs used for N. benthamiana expression.  
Constructs contained several elements for expression. The four constructs are for the M-
ER, M-ELP, M-HFBI, and M-Apo protein products. The constructs included a double 
enhanced cauliflower mosaic virus promoter (2x35S) (Covey et al., 1981), and a 
translational enhancer from tobacco (tCUP) (Wu et al., 2001). Two of the constructs 
targeting the ER also contained sequences encoding an elastin-like polypeptide (ELP) or 
a hydrophobin (HFBI) tag with a linker (L). Two tags were included for 
immunodetection, N-terminal Xpress and C-terminal c-Myc. For subcellular targeting, 
tobacco pathogenesis-related-1b signal peptide (PR1b) (Huub and Van Loon, 1991) and 
the KDEL ER retrieval tetrapeptide were used. The schematic is not to scale.  
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Figure 4. Western blot of M expressed with various expression constructs.  
A band of the expected size, 43 kDa is observed for M-ELP-ER, but not for the other 
three constructs. GP5-GFP, a recombinant protein successfully produced previously, was 
used as a positive control. The arrow points to the barrier between the stacking and 
separating gel. Protein was extracted with PEB from three biological replicates, labelled 
as 1, 2, and 3, and run on 4% stacking, 12% separating polyacrylamide gels. This and all 
subsequent membranes were probed with anti-c-Myc primary antibody and goat anti-
mouse secondary antibody  
40 
  
membranes and lost during soluble protein extraction.  
3.1.2 Extraction and Detection Choice 
As the M protein has three transmembrane domains and probably embeds in plant cell 
membranes, alternative extraction methods were explored. Bünger et al. (2009) compared 
five different commercial extraction kits for their ability to isolate and purify membrane-
bound proteins. The study found the Qproteome® Cell Compartment Kit by Qiagen and 
the ProteoExtract® Native Membrane Protein Extraction Kit by EMD Millipore most 
effective. EMD Millipore’s kit has been successfully tested on plant tissue, while 
Qiagen’s has not been tested on plant tissue (Qian et al., 2008). Thus, EMD Millipore’s 
kit was used to see if more M protein could be detected. The kit gives two protein extract 
fractions, one with soluble proteins, and one with membrane-bound proteins. As before, 
no protein accumulation was observed for any construct other than ELP-ER (Figure 5). 
More M-ELP was detected than with the previous extraction buffer. M-ELP was 
observed at the correct size of approximately 43 kDa in the soluble fraction, but potential 
dimers were also detected. In the membrane fraction, a large amount of aggregates of 
various molecular weights were present. Because the ELP-ER cassette was the only one 
that resulted in M protein accumulation, this construct was used exclusively for the rest 
of this study. 
Lee et al. (2005) documented that the SARS-CoV M protein undergoes aggregation when 
heated in denaturing buffer, therefore it was hypothesized that heating may be the cause 
of the aggregates observed in the membrane-bound fraction. To test this hypothesis, 
protein extracts were separated by gradient PAGE, omitting the heating step of the 
procedure (Figure 6). This resulted in far fewer aggregates in the membrane-bound 
fraction, and more protein instead being detected at the correct molecular weight. Hence 
protein was not boiled any longer before loading onto SDS-PAGE gels. When extracts 
were not boiled, potential dimers and trimers became evident in place of thermal 
aggregates. Gradient gels were also used henceforth for clear separation of multimers. 
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Figure 5. Extraction of infiltrated constructs with commercial membrane protein 
extraction kit.  
N. benthamiana tissue was infiltrated with four different constructs and proteins were 
extracted with EMD Millipore’s ProteoExtract® Native Membrane Protein Extraction 
Kit. Each extraction resulted in one fraction containing membrane-bound proteins (M), 
and one fraction containing soluble proteins (S). The only construct that showed protein 
accumulation is the M-ELP-ER construct. Using this kit, more protein was visualized 
than previously with PEB (Figure 4). Protein was separated on 4-20% gradient 
polyacrylamide gels. 
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Figure 6. M-ELP extracted with commercial kit, and both boiled and unboiled.  
Three biological replicates were extracted, and the membrane-bound fraction (M) and 
soluble fraction (S) of each were separated on gradient PAGE. The membrane-bound 
fraction of each was also not boiled to compare effects on protein aggregation. Higher 
molecular weight aggregates were observed in the membrane fraction, but more protein 
ran at the expected size when the extract was not boiled prior to running the gel (solid 
arrow). When extracts were not boiled, potential dimers and trimers became evident 
(empty arrowheads).  
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As extracts were not boiled, to ensure that the stronger 43 kDa protein band observed is 
M-ELP and not a plant peroxidase that would catalyze the chemiluminescent reaction 
used for detection, with a new set of samples the soluble and membrane-bound protein 
extract fractions were dotted directly on a nitrocellulose membrane (Figure 7). Enhanced 
chemiluminescence (ECL) substrate was applied, and it became evident that peroxidase 
was present when protein was not boiled. More peroxidase was detected in the soluble 
fractions than in the membrane-bound protein fractions. 
The previous experiment was then repeated, and the membrane was incubated with ECL 
substrate before probing with primary antibody. No peroxidase was observed on the 
membrane exposed to ECL substrate before probing in either boiled or unboiled lanes 
(Figure 8). As before, the protein is observed after the blot is hybridized with the 
appropriate antibodies and detected with ECL substrate. Thus, the increased amount of 
protein detected at 43 kDa without boiling is in fact M-ELP. Perhaps particularly with dot 
blots, presence of plant peroxidase should be monitored. 
To develop an extraction buffer and not rely on a commercial buffer with unknown 
composition, several buffer components for enhanced membrane protein extraction were 
investigated. Buffer choice is important to maintain the stability of proteins at the chosen 
pH and ionic strength. Proteins are denatured easily once no longer in the cell, and can be 
sensitive to pH changes (Cseke et al., 2011). Buffering capacity is important when acidic 
plant cell vacuoles are burst during the extraction procedure, to ensure buffer pH does not 
drop from the ideal range. pH 8 was chosen to avoid protein precipitation due to M-
ELP’s isoelectric point of 6.65. Tris was chosen as a buffer due to its buffering range of 
pH 7.5-9, and because it increases membrane permeability, which can help in the 
solubilisation of membrane proteins (Irvin et al., 1981). Detergent choice is a key 
component when optimizing an extraction buffer, as detergents disrupt membranes, and 
thus are necessary to solubilize a membrane protein (Arnold and Linke, 2008). Protein 
was extracted in a Tris-based buffer that contained either non-ionic detergents (1% Triton 
X-100, 1% Brij 35, 1% Tween-20), a harsh denaturant (7 M urea/2 M thiourea/4% 
CHAPS), or no detergent/disruptant.  
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Figure 7. Dot blot showing presence of plant peroxidase in unboiled protein extracts.  
Most of the peroxidase is in the soluble protein extract. Plant peroxidase is not increased 
with viral membrane protein expression, it is found with both M-ELP and p19 
infiltration, and just infiltration of p19 (negative control). S, soluble protein fraction, M, 
membrane-bound protein fraction. Protein was extracted with EMD Millipore’s 
ProteoExtract® Native Membrane Protein Extraction. 
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Figure 8. Western blot detected before and after probing to look for peroxidase 
activity.  
(a) ECL substrate was applied after blocking the membrane but before probing. Neither 
the negative control (p19) nor M-ELP lanes have any peroxidase detected in the soluble 
(S) or membrane-bound (M) protein extraction fractions. (b) As before, more protein is 
observed in the membrane-bound fraction (Figure 6). When protein is not boiled prior to 
loading gel, less aggregation is observed. p19 protein extracts were not boiled. Protein 
was extracted with EMD Millipore’s ProteoExtract® Native Membrane Protein 
Extraction Kit from three biological replicates, (1, 2, and 3). 
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Using dot blots, the amount of protein in each extract was quantified as mg of protein per 
g of fresh leaf weight. Tween-20 and Triton X-100 extracted the highest levels of protein, 
at 0.80 ± 0.43 mg/g and 0.75 ± 0.39 mg/g of fresh leaf weight, respectively (Table 7). 
The difference between protein extracts was visible, with no detergent and Tween-20 
having the palest extracts, and SDS and the urea extract appearing a darker green, 
indicating lysis of the chloroplast membrane (data not shown). 
To determine if the effects of the detergents on M-ELP extraction were significantly 
different among treatments, a balanced ANOVA was performed, which takes in to 
account variability between replicates. For this, the log value of the protein 
accumulations was used to satisfy the assumptions of homoscedasticity. A balanced 
ANOVA showed that accumulation levels between extraction methods were significantly 
different (p < 0.001). Tukey Pairwise Comparisons were performed to determine which 
treatments were significantly different from each other. Buffers with detergents extracted 
significantly more protein than when no detergent was used, but the difference between 
detergents was not significant (Figure 9). Use of detergent resulted in an over 350x 
increase in the amount of protein extracted, and choice of detergent resulted in a 4-fold 
increase in the amount of protein extracted (Table 7). 
Tween-20 and Triton X-100 became prime candidates for future experiments. After this 
experiment was performed, the composition of EMD Millipore’s protein extraction kit 
was released, and reported to use Triton X-100 as its detergent. Due to Triton X-100’s 
success in extracting M protein, its commercial use, its utility in phase separation, and to 
stay consistent with VLP extraction protocols, which use Triton X-100, it was the 
detergent used for further experiments. 
Research has shown that sucrose can stabilize proteins by increasing the activation 
energy of protein unfolding. Sucrose is preferentially excluded from protein domains, 
thus increasing the free energy of solutions, and making the unfolded state of proteins 
less favourable (Lee and Timasheff, 1981). Another set of extractions was performed to 
compare Tris-based buffer with 1% Triton X-100, with and without sucrose, to EMD 
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Table 7. Protein extraction levels with different detergents/disruptants. 
Detergent/Disruptant Used Accumulation of M-ELP in mg/g of fresh 
weight leaf tissue1 
7M urea, 2M thiourea, 4% CHAPS 0.620 ± 0.30 
1% Triton X-100 0.748 ± 0.388 
1% Tween-20 0.800 ± 0.433 
1% Brij35 0.202 ± 0.012 
No detergent 0.00214 ± 0.00142 
1Mean value of three biological replicates, ±, standard error of the mean value of the 
three biological replicates. 
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Figure 9. Comparison of protein extraction levels with different 
detergents/disruptants.  
Triton X-100 and Tween-20 extracted significantly more protein than the other extraction 
methods, and all detergents extracted significantly more protein than extraction without 
detergent. Each column represents the mean value of three biological replicates and error 
bars indicate the standard error of the mean. Means that do not share a letter are 
significantly different (F5 = 21.16, p < 0.001). 
 
  
a
a
a
a
b
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
7M Urea, 2M
Thiourea, 4%
CHAPS 1% Triton X-100 1% Tween20 1% Brij35 No Detergent
M
-E
LP
 (
lo
g 
va
lu
e 
o
f 
m
g
/g
 o
f 
F.
W
.)
Detergent
49 
  
Millipore’s kit. Protein extraction values for the soluble and membrane-bound fraction 
were pooled and compared to the single extraction values of the lab buffer protein 
extracts (Table 8).  
The Tris-based buffers extracted more protein than the commercial buffers despite 
resulting in a paler extract (data not shown). The addition of sucrose had a positive 
impact, but the differences between the extractions were not significantly different [F2 = 
1.21, p >0.39]. Due to the observed trend of increased extraction with sucrose, and its 
inclusion in the commercial kit, sucrose was added to the composition of FEB.  
Lastly, the effect of increasing the detergent concentration in the lab buffer was studied. 
Increasing the concentration of the detergent marginally increased the amount of protein 
detected, evidenced by comparing the detection of degraded protein products (Figure 10). 
Due to any potential increase in the amount of protein extracted Triton X-100 
concentration was increased to 1.5%.  
3.2 VLP Formation 
3.2.1 In silico Analysis of M and M-ELP 
Having determined that M-ELP is produced in N. benthamiana at above 0.7 mg/g of fresh 
leaf weight, the next objective to examine was whether M was assembling into VLPs. 
While M from SARS-CoV and TGEV was shown to independently assemble into VLPs 
(Tseng et al., 2010; Zhenhui et al., 2015), it is unknown if a fusion of PEDv M with ELP 
would assemble into VLPs. Therefore, the structure of the fusion protein was compared 
to the native protein structure by in silico protein structure prediction software.  
The I-TASSER 3D protein prediction software (Zhang, 2008) using the PSSpred 
algorithm predicted that the beginning of the native protein was a short coil (1-7), 
followed by three helices, representing the transmembrane segments (8-34, 44-65, 76-
105) with coils in between each, and a long C-terminal coil-strand mix (Figure 11a). This 
gave further insight into what had been previously reported about coronavirus M 
structure. Previous predictions have suggested that the N-terminal outside the virus  
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Table 8. Protein extraction levels with lab and commercial buffers. 
Extraction Buffer Used Accumulation in mg/g of fresh weight 
leaf tissue of M-ELP1 
1% Triton X-100 0.57 ± 0.17 
1% Triton X-100 (with sucrose) 0.73 ± 0.17 
Combined Soluble and Membrane fractions 
of ProteoExtract® Native Membrane 
Protein Extraction Kit 
0.49 ± 0.056 
1Mean value of three biological replicates, ± standard error of the mean value of the three 
biological replicates.  
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Figure 10. Visual comparison of differences in Triton X-100 based buffers.  
It is observed that increasing the concentration of Triton X-100 potentially increases the 
amount of protein detected on a Western, particularly when comparing degraded protein 
products. 
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Figure 11. Predicted protein structures of M and M-ELP.  
(a) Native M amino acid sequence and PSSpred predicted protein structure, showing the 
characteristic three helices that represent the transmembrane segments.(b) M-ELP amino 
acid sequence and PSSpred predicted protein structure, showing the three helices, as well 
as extended N-terminal and C-terminal fusions. Numbers represent the predicted 
confidence score from 1-10. C, coil; H, helix; S, strand. 
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stretched from amino acid positions 1-17. This analysis instead suggested that this 
domain was made up of only amino acids 1-7. This led to a difference in the length of the 
transmembrane domain that had previously been reported. Previously, transmembrane 
segments were predicted to be amino acid sequences 18-38, 42-62, and 76-96 (The 
UniProt Consortium, 2015). With no coronavirus membrane proteins submitted to the 
Protein Data Bank database, neither estimate is definitive.  
Using the same software to compare the structure of M-ELP, the N-terminal coil and the 
triple transmembrane segments separated by coils were preserved. The N-terminal 
additions (att sites and Xpress tag) are predicted to result in an additional coil at the N-
terminus, and the addition of the ELP polypeptide results in an extension of the C-
terminal coil (Figure 11b). Whether there is an impact on the typical coronavirus M 
protein amphipathic domain inside the virus is not clear, as this was not predicted for the 
native or fusion protein. With the fundamental structure of the protein predicted to be 
unchanged, the potential for M-ELP to form VLPs as native coronavirus M protein was 
explored.  
3.2.2 Expression of S, N, E, and Co-Expression 
To determine whether VLPs can be produced through co-expression of several proteins, 
it was first necessary to determine which proteins could be produced in N. benthamiana. 
The genes for the three remaining structural proteins, N, S, and E were cloned into ELP-
ER construct since the ELP fusion was the only gene construct that expressed with M. 
These gene constructs were expressed transiently by agroinfiltration in N. benthamiana, 
and protein was extracted six days post-infiltration. Recombinant proteins were separated 
by SDS-PAGE and analyzed by immunoblotting. 
The M-ELP lane showed the expected 43 kDa band, but additionally showed a smaller 
band above 25 kDa (Figure 12). While degradation products had previously been 
observed, for example in Figure 10, a clear single smaller band had not been detected. 
The observed band is likely a result of proteolytic cleavage (see 3.2.3.2). 
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Figure 12. Expression of all four PEDv structural genes.  
M-ELP and E-ELP are clearly detected. A smaller than expected band is observed 
alongside the monomer and a putative peroxidase band for M-ELP, and E-ELP is found 
to accumulate as a monomer and dimer. There is putative plant peroxidase observed in all 
lanes just under 37 kDa in size. Bands larger than the potential plant peroxidase are 
observed in the N-ELP lane, but these bands are smaller than the expected size of 66.6 
kDa. S-ELP is predicted to be 169.4 kDa, and neither full size S nor a breakdown product 
were observed. Protein was extracted with FEB from pooled leaf tissue from three plants 
with FEB. 
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The E-ELP construct showed a major band of the predicted size as well as a putative 
dimer (26 kDa and slightly larger than 50 kDa, respectively). N-ELP showed two diffuse 
bands at ca. 37 and 45 kDa, instead of the expected 66.6 kDa, and S-ELP did not produce 
any protein (Figure 12). All lanes showed a band smaller than 37 kDa thought to be plant 
peroxidase, due to its presence in the wild type tissue extract.  
Previous coronavirus studies have indicated that M and E, and sometimes N, are critical 
to VLP formation (Ho et al., 2004; Huang et al., 2004). Since M-ELP, E-ELP and 
possible N-ELP were produced in N. benthamiana, co-expression studies were 
conducted. Aside from expression of each construct alone, three combinations of gene 
constructs were co-expressed: M-ELP with E-ELP, M-ELP with E-ELP and N-ELP, and 
M-ELP with E-ELP, N-ELP, and S-ELP. While it was clear that S-ELP was not 
accumulating on its own (Figure 12), all four structural proteins were co-expressed to 
assess whether this could assist in S-ELP accumulation.  
To confirm whether the consistent 35 kDa band observed in Figure 12 was plant 
peroxidase, and whether the bands around 37 kDa in the N-ELP extract were breakdown 
products of N-ELP or plant peroxidase aggregates, the protein extracts were run on 
another PAGE and the membrane was treated with the ECL substrate prior to antibody 
binding. Knowing that E-ELP was also able to express, co-expression studies also began. 
The proposed 35 kDa peroxidase band in Figure 12 was found in every sample in Figure 
13a, confirming that it is a plant peroxidase catalyzing the chemiluminescent reaction. 
The larger bands in the N-ELP extract were not observed, indicating that they correspond 
to cleavage products of N-ELP. The band in the M-ELP extract just larger than 25 kDa is 
also not present, indicating it is likely a hypothesized cleavage product of M-ELP. It has 
previously been reported that the M protein of TGEV  undergoes N-terminal proteolytic 
cleavage (Laude et al., 1987). While this is not expected for PEDv M due to the lack of 
predicted signal sequence, incubation with Triton X-100 is suggested to make a protease 
cleavage site accessible, leading to the presence of a fragment (Utiger et al., 1995). Based 
on previous reports, cleavage of M-ELP should result in an N-terminal fragment of 23.61 
kDa, and a C-terminal fragment of 19.39 kDa (Utiger et al., 1995). The fragment detected 
most strongly is instead observed to be slightly larger than 25 kDa (Figure 13a).   
56 
  
 
Figure 13. All four structural genes, individually and co-expressed, with ECL 
substrate before and after antibody hybridization.  
(a) The PVDF membrane was treated with ECL substrate before antibodies were 
hybridized to proteins. Bands show presence of plant peroxidase, catalyzing the ECL 
reaction. A consistent band slightly smaller than 37 kDa is observed in all lanes, this 
same band is observed in Figure 12. A band just above 20 kDa is also present in all lanes, 
and a band between 50 and 75 kDa is present in all lanes except wild type (non-
infiltrated) tissue, and potentially M-ELP+E-ELP+N-ELP. (b) The M-ELP lane shows 
smaller degradation products, as well as the putative cleavage product larger than 25 kDa, 
and monomer. The 35 kDa and 50+ kDa peroxidase bands are observed more clearly than 
expected. The N-ELP, E-ELP, S-ELP and wild type (non-infiltrated) tissue lanes show 
the same banding patterns as in Figure 12. When proteins were co-expressed the banding 
patterns of the respective proteins were all found, with the N-ELP fragments detecting 
most strongly when all four proteins were co-expressed. In contrast, M-ELP and E-ELP 
bands are weaker with the co-expression of N-ELP or N-ELP and S-ELP. Protein was 
extracted from pooled leaf tissue from three plants with FEB. 
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In order to verify the identity of the detected protein, mass spectrometry analysis was 
performed. Analysis of the putative fragment resulted in peptide spectra matching to 
three areas of M-ELP, the N-terminal of the protein (a.a. 19-37), across the middle of the 
protein, in M-ELP’s intravirion tail (a.a. 176-,194, 194-203, 206-221, 223-242), and to 
the C-terminal c-Myc tag and ER retention sequence (a.a. 409-420). Finding that the >25 
kDa band contains peptides from both the N- and C-terminal of M-ELP may indicate that 
fragments of the protein are self-associating to give the observed >25 kDa band.   
In addition, a band slightly larger than 50 kDa is found in several lanes of the blot. While 
it is barely visible in the M-ELP and N-ELP extracts, it is pronounced in the E-ELP 
extract, and to a lesser extent, in the S-ELP lane, and visible when protein extracts 
involve either protein. This band may represent a different peroxidase that is induced by 
specific viral protein expression (G. Lomonossoff, personal communication).  
The membrane was then washed, probed with primary and secondary antibodies and 
imaged by chemiluminescence. The 35 kDa putative peroxidase band is far fainter than 
before probing. Though in Figure 13b the membrane was imaged for a sixth of the time, 
the amount of light captured was over five times higher. This indicates that recombinant 
protein bands are stronger, with the faint 20 kDa band of Figure 13a no longer showing in 
all lanes. The truncated M-ELP product here is distinctly smaller than the peroxidase 
band. Other bands are also observed in the M-ELP lane which may represent the smaller 
and larger peroxidase bands in Figure 13a.  
The putative E-ELP dimer migrates at a similar size to the peroxidase in Figure 13a; 
however it is a much tighter band. It is clear that this band is in fact E-ELP, as the 50+ 
kDa putative peroxidase band is very faint in co-expressed protein lanes in Figure 13a, 
but is clearly visible in all three co-expressed lanes in Figure 13b. Mass spectrometry 
analysis of the putative E-ELP dimer band confirmed the presence of E-ELP, confirming 
that E-ELP is forming a dimer (Appendix 2). No peroxidase of the correct molecular 
weight was detected in the protein composition of the band, likely because the peroxidase 
observed in Figure 13a is present at levels below the detection limits of the mass 
spectrometry equipment.  Thus the tight >50 kDa band observed in Figure 13b is 
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primarily composed of the E-ELP dimer. Co-expression of M-ELP and E-ELP resulted in 
detection of the E-ELP monomer and dimer, M-ELP monomer, and the 35 kDa 
peroxidase band. Co-expression of N-ELP, or N-ELP and S-ELP with M-ELP and E-ELP 
results in the detection of N-ELP fragments. These fragments detect most strongly when 
all four proteins are co-expressed. When all four proteins are co-expressed M-ELP and E-
ELP bands detect less strongly, likely as the A. tumefaciens OD600 of each construct is 
decreased. 
It became apparent through these experiments that leaves that had been infiltrated with E-
ELP were much paler post-infiltration than leaves that had been infiltrated with M-ELP. 
This phenomenona persisted when M-ELP and E-ELP were co-expressed (Figure 14abc). 
This potentially is due to the upregulation of the >50 kDa peroxidase.  
When proteins were extracted with the commercial kit, as opposed to FEB (Table 4) like 
in Figure 13, a laddering effect was observed (Figure 15b). When M-ELP and E-ELP are 
co-expressed the laddering bands are stronger than those in the M-ELP/N-ELP/S-ELP/E-
ELP extract, similar to what was observed in Figure 13a. With no S-ELP or N-ELP 
accumulation observed, infiltrating all four genes together meant that the number of 
Agrobacterium bacteria carrying each construct was reduced, thus leading to a reduction 
in protein accumulation of M-ELP and E-ELP. This provides evidence that laddering is 
an effect of M-ELP and E-ELP co-expression. A time course was also performed, 
showing the highest amount of protein accumulation six days post infiltration for M-
ELP+E-ELP lanes, and four days post infiltration for co-expressed M-ELP+E-ELP+N-
ELP+S-ELP lanes. M-ELP only lanes did not have discernibly different accumulation 
between days 4 and 6, but both days show higher accumulation than day 2.  
In the M-ELP+E-ELP lanes, bands the size of the E monomer and dimer were observed 
(one and two squares, Figure 15b), but a band was not detected at the size of the M 
monomer , rather a band at ca. 80 kDa was observed that might correspond to a dimer of 
M (one and two diamonds, Figure 15b). This dimer was also the only recombinant 
protein observed in the M-ELP only lanes. This was the only time M-ELP was only  
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Figure 14. N. benthamiana leaf infiltrated with M-ELP, E-ELP, or M-ELP and E-
ELP.  
(a) M-ELP infiltrated leaf. The leaf is lighter post-infiltration, but not to a large degree. 
(b) E-ELP infiltrated tissue. The leaf is much lighter than before infiltration. (c) M-ELP 
and E-ELP infiltrated leaf tissue (left side of the leaf) and p19 (right side of the leaf, 
negative control). The yellowed leaf phenotype seen with E-ELP infiltrated tissue is 
maintained when both constructs are infiltrated together, and is clearly not due to the 
infiltration of p19.   
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Figure 15. Co-expression of PEDv proteins, and time course.  
Extraction of co-expressed proteins with the commercial kit showed a laddering effect 
was possible. (a) Membrane before probing. ~35 kDa peroxidase band is observed, and 
the 20 kDa band is observed faintly. (b) M-ELP and E-ELP co-expression showed the 
highest accumulation of protein on day six. Bands are lighter when all four proteins are 
co-expressed, due to lower OD600 of each construct being infiltrated. Protein 
accumulation was highest on day four when all four proteins were co-expressed. E-ELP 
monomer and dimer size bands are observed (one and two squares). When M is 
expressed alone or together with E-ELP, the M-ELP monomer is not observed (one 
diamond), but a dimer is (two squares). M-ELP only tissue shows the highest amount of 
protein four or six days post infiltration (DPI). Wild type (non-infiltrated) tissue is the 
negative control; B, blank lane; DPI, days post infiltration. Protein was extracted with 
ProteoExtract® Native Membrane Protein Extraction Kit, membrane extract for one of 
three plants is shown.  
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observed as a dimer, and may correlate to the observed laddering. The higher molecular 
weight bands observed on this blot likely indicate multimerization and VLP formation. 
The lanes with all four constructs showed a band a band the size of the M-ELP monomer, 
potentially the result of reduced protein accumulation and interaction. 
To determine if these samples showed any difference in peroxidase expression, the 
membrane was imaged before and after antibody probing. The pre-probed membrane in 
Figure 15a shows the ~35 kDa and ~20 kDa peroxidase bands observed previously, but 
the 50+ kDa band was notably absent from the M-ELP + E-ELP extracts. This is different 
than what was observed in Figure 13, where E-ELP seemed to cause production of a 
peroxidase with a molecular weight above 50 kDa. Despite the laddering detected on the 
probed blot, peroxidase size is not affected.  
3.2.3 VLP Formation 
3.2.3.1 Sucrose Gradient Analysis 
Knowing that both M-ELP and E-ELP are produced in N. benthamiana leaves, and that a 
laddering effect was observed which could mean that the proteins are assembling into 
higher order structures, the possibility that VLPs were being assembled in plant cells was 
explored. For this, leaf tissue was vacuum-infiltrated with either M-ELP, or M-ELP and 
E-ELP, and 8 g of infiltrated and wild type tissue was harvested four days post-
infiltration. Protein was extracted in VLP Extraction Buffer (Table 4), and the protein 
extract was spun in an ultracentrifuge through a 30-60% discontinous sucrose gradient to 
concentrate any VLPs (Figure 16).  
The resulting gradient was fractionated into 1 ml aliquots, and samples were analyzed by 
immunoblot. The full-length M-ELP protein was detected strongly in all fractions, with 
the highest amount of protein in the 40% fraction. The 25 kDa cleavage product 
previously observed was detected less in the heavier sucrose gradient fractions, which 
would contain sedimented VLPs (Figure 17a). Truncated M-ELP not being detected in 
heavier sucrose fractions may indicate that the protein is not being incorporated into 
VLPs. Previous literature has noted that the M fragment does not incorporate into virions 
(Utiger et al., 1995). As peptide spectra coverage did not match to the transmembrane  
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Figure 16. Protein extract ultracentrifuged through a sucrose gradient.  
(a) 24 ml of protein extract loaded onto 12 ml of discontinuous sucrose gradient. (b) After 
the spin, each gradient is clearly shown, as well as the supernatant. From the bottom up, 
arrows indicate the interphase between the 60%, 50%, 40%, 30% sucrose and supernatant 
fractions. VLPs were expected to be found in the 40% fraction. Protein was extracted 
from leaf tissue with the VLP Extraction Buffer. 
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Figure 17. Immunoblot analysis of sucrose gradient fractions of M-ELP and M-
ELP+E-ELP protein extracts.  
(a) M-ELP is observed throughout all the fractions and in the supernatant. The M-ELP 
band in the 40% fraction appears heaviest. The expected band of 43 kDa is observed, as 
well as the cleavage product band just above 25 kDa. (b) Bands of the correct size are 
observed for M-ELP and E-ELP monomers, and the E-ELP dimer. The 40% fraction is 
observed to have the most protein overall. 
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domains, PEDv M may require these domains for inter-M interactions, as has been 
reported for MHV (de Haan et al., 1998) 
Analyzing the sucrose gradient fractions of co-expressed M-ELP and E-ELP showed the 
combined banding pattern of the M-ELP monomer and the E-ELP monomer and dimer. 
The highest amount of total detected protein in this protein extract is also in the 40% 
fraction; the E-ELP and M-ELP monomers are heaviest at 40% sucrose, and the putative 
E-ELP dimer is heaviest at 30% sucrose (Figure 17b). The smallest band of the M-
ELP/E-ELP sucrose gradient was analyzed, and found to contain both E-ELP, and the 
truncated M-ELP Spectral counts were used to determine relative protein amounts. In the 
30% fraction, where the most truncated M-ELP would be expected, it was found that 
there was twice as much E-ELP than M-ELP present. This ratio likely increases in the 
heavier sucrose gradients based on the pattern observed in Figure 17a. The wild type 
extract showed no protein in most of the fractions, with the exception of the 30% fraction 
where, the 35 kDa peroxidase band was observed. As both M-ELP and M-ELP+E-ELP 
extracts showed the highest amount of protein at 40% sucrose, the same density where 
PEDv virions are expected to be found (Hofmann and Wyler, 1989), these fractions were 
the primary choice for TEM analysis.  
3.2.3.2 VLP Analysis 
The final question that needed to be addressed was whether M-ELP or the combination of 
M-ELP and E-ELP would assemble into VLPs. For this, the 40% fraction from the 
sucrose gradients of both treatments and the wild type were analyzed by TEM. The 40% 
fraction of M-ELP extract was found to contain circular particles (Figure 18a). While 
native virions, excluding spike projections are just larger than 100 nm, M VLPs for 
SARS were observed to be 50 nm in diameter (Tseng et al., 2010). The particles observed 
in Figure 18a were also about 50 nm in diameter. A distinct feature of coronaviruses is 
that M forms a lattice in the viral envelope, resulting in a membrane twice the thickness 
of typical biological membranes (4 nm) (Bárcena et al., 2009). The particles observed 
have an envelope thickness of approximately 9.3 nm. The size and envelope thickness of 
the particles indicates that these are VLPs formed with only the M protein of PEDv.  
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Figure 18. TEM and Immungold TEM analysis of 40% sucrose gradient fractions.  
(a) M-ELP protein extract. VLPs observed are approximately 50 nm. (b) M-ELP+E-ELP 
protein extract. VLPs are observed to be approximately 80-85 nm in size. (c) 
Immunogold labelled M-ELP protein extract, using anti-c-Myc primary antibody. Gold 
particle bound secondary antibodies are able to bind to burst VLPs (evidenced by partial 
membrane structure), as the C-terminal of M-ELP is exposed. No antibody is able to bind 
to the intact VLP at the bottom of the picture. (d) Wild type tissue protein extract. No 
VLP structures observed. 
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Extracts of co-expressed M-ELP and E-ELP showed similar particles. Figure 18b shows 
that when the two proteins were co-expressed, VLPs were larger than with M-ELP alone. 
The larger size correlates to what has been presented in the literature, with MHV M+E 
VLPs having diameters of approximately 75 nm (Neuman et al., 2011). The VLPs 
observed in Figure 18b have a thick membrane of 10.1 nm, and are approximately 80 nm 
in diameter, suggesting they are VLPs. To provide further proof that the observed 
structures are VLPs containing M-ELP, immunogold TEM was done with the same M-
ELP extract as above. Extracts had been frozen since previous grid preparation, and this 
reduced the total number of VLPs. The primary antibody used for detecting M-ELP is a 
commercial c-Myc tag antibody. This was not ideal, as the c-Myc tag is at the C-
terminus, which folds inside the VLP. Previous reports have shown that using a C-
terminal antibody on M results in no binding when virions are intact, but that binding can 
be observed on burst virions (Utiger et al., 1995). Similarly, it was observed that c-Myc 
antibody was able to bind to burst but not intact structures, giving further evidence that 
the structures are VLPs, and that protein is folding in the correct conformation (Figure 
18c). Thus, VLPs are thought to have been produced for PEDv with expression of M and 
E, or with just M alone as ELP fusion proteins. These results may add to the evidence 
that coronavirus VLPs can be produced with only the M protein.    
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4 Discussion 
4.1 PEDv vaccine design 
The goal of this study was to produce a plant-made vaccine candidate to immunize pigs 
against PEDv. Previous work has focused on the S protein. As M is less prone to 
mutations (Sato et al., 2011), has an epitope (Zhang et al., 2012), and is involved in viral 
assembly (de Haan et al., 2000), M, and M based VLPs were the focus for this study’s 
vaccine design. Future work can focus on optimizing N and S expression to then produce 
VLPs with all four proteins. The results show that high accumulation levels of M are 
attainable using plants as bioreactors with the use of a fusion tag, and that M-ELP is able 
to form VLPs independently, as well as together with E-ELP. 
4.2 Transient production of M 
One of the findings of this study was that the addition of the ELP tag was necessary to 
detect any accumulation of M transiently produced in N. benthamiana. ELP tags are not 
susceptible to proteolysis, and are hydrophilic and soluble (Raucher and Chilkoti, 2001). 
As such, ELP tags allow the accumulation of higher levels of M by either protecting the 
fused protein from proteolysis, or increasing solubility of the whole protein, potentially 
allowing for increased stability. 
While the hydrophobin tag has worked in increasing recombinant protein accumulation 
previously (Joensuu et al., 2010), no protein was detected when M was fused with a 
hydrophobin tag, indicating increased accumulation is protein specific, as previously 
found (Pereira et al., 2014).  
ELP has a positive effect on accumulation levels for the ER-targeted protein, but not for 
protein targeted to the cytoplasm, apoplast, or chloroplast (Conley et al., 2009b). As such, 
ELP was only fused to M in the construct targeting the ER. As no recombinant protein 
was detected when M was directed to the apoplast or ER without ELP, it is suggested that 
ELP is the main source of increased protein accumulation. 
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Having recombinant protein accumulate in the ER is beneficial. Targeting recombinant 
protein to the ER rather than the extracellular space in tobacco has shown to result in 
increased accumulation levels from 10 to 20 fold (Fiedler et al., 1997). It has been 
suggested that incorrectly folded proteins in the ER are degraded. This indicates that ER 
retention can promote correct protein folding, leading to less degradation and higher 
stability. Further, ER retention allows stable storage of recombinant proteins that retain 
their activity after lyophilisation (Fiedler et al., 1997). The ERGIC is where PEDv virions 
naturally bud off. Targeting M-ELP to the ER may assist in the interaction of M-ELP 
proteins, or M-ELP and E-ELP proteins, resulting in VLP formation.  
M-ELP was found in both soluble and membrane-bound protein extracts (Figure 6). 
Protein found in the membrane-bound fraction is likely M-ELP that is retained in the ER, 
or VLPs that have not been secreted extracellularly, while soluble M-ELP may be 
detected due to the formation of soluble secreted VLPs. 
Full length M has been difficult to express, and this is the first time it has been reported 
to be expressed in plants. Given the high levels of accumulation and the expanding 
knowledge of coronavirus replication, this may be an ideal protein to study membrane 
protein expression in plant cells, to better understand heterologous transmembrane 
segment identification by translocons, and to reach a better understanding of why some 
membrane proteins express better than others in eukaryotic systems. 
4.3 Extraction of M-ELP 
M-ELP was observed to form aggregates when boiled. When protein was not boiled 
before separation by PAGE, fewer high molecular weight aggregates and more protein at 
the monomer size was observed, as well as distinct dimer, trimer and tetramer size bands. 
Thermal aggregates have been observed for M of another coronavirus, SARS-CoV. Lee 
et al. (2005) found that boiling M caused aggregation in the stacking gel. The 
hydrophobic regions of SARS-CoV M were necessary for this thermal aggregation to 
occur, and the addition of reducing agent had no effect on aggregation. That the 
transmembrane domains of SARS-CoV M were needed for thermal aggregation may be 
related to roles the transmembrane domains have in protein interaction. However the 
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transmembrane domains also play a critical role in protein interaction for MHV, although 
this virus does not form thermal aggregates (de Haan et al., 2000; Lee et al., 2005). 
Further research may detail the mechanisms behind the observed aggregation.  
Higher molecular weight bands were only observed in M-ELP extracts when EMD 
Millipore’s ProteoExtract® Native Membrane Protein Extraction Kit was used. 
Formation of discrete M oligomers has also been shown for HCoV 229E, where 
reduction-sensitive complexes with molecular weights corresponding to two, four, and 
eight copies of M were reported (Arpin and Talbot, 1990). Given the importance of M-M 
interactions on virion formation, the formation of these complexes is logical. The 
cysteine in M was hypothesized to play a role in forming intermolecular disulfide 
bridges. PEDv M protein has two cysteines, at positions 85 and 129 (Figure 11). The 
second cysteine is likely significant, as it is on the cytoplasmic tail, which was proven to 
be crucial in VLP formation (de Haan et al., 1998). PEB, DSB and FEB contain sodium 
L-ascorbate, which can reduce disulfide bridges (Giustarini et al., 2008), while the 
commercial kit does not have a similar reagent. The lack of a compound that can break 
disulfide bridges may allow the formation of M-ELP complexes. While all protein 
extracts were stored in sample buffer with DTT, a reducing agent, the reducing ability of 
DTT is limited at pH 7 or below. Both extraction buffers of the commercial kit have a pH 
of 7.2, at which point the activity of DTT may be suboptimal, explaining the detection of 
higher molecular weight complexes. This pH may also be too close to the isoelectric 
point (pI) of M-ELP, 6.65. When the pH of a solution is the same as a protein’s pI, the 
protein is no longer charged, and will aggregate and precipitate (Xia, 2007). To avoid 
precipitation of recombinant protein, a final pH of 8 was used for FEB. 
Extracting membrane proteins is difficult (Carpenter et al., 2008), and established 
protocols are not focused on extracting membrane proteins from plants (Arnold and 
Linke, 2008). Thus it was necessary to have an optimized extraction buffer to accurately 
quantitate M-ELP accumulating in N. benthamiana leaves. Detergents are known to be 
key components of the extraction buffer for membrane proteins (Arnold and Linke, 
2008). This study found that the addition of detergent made a difference of 0.798 mg/g of 
protein detected per fresh weight of leaf, a 350x increase over an extraction buffer with 
70 
  
no detergent (Table 7). Non-ionic detergents often strike the middle ground between not 
denaturing proteins, and efficiency in covering the hydrophobic surface of membrane 
proteins. The commercial kit uses 0.5% Triton X-100 as its detergent. Triton X-100 is 
widely used as a non-denaturing detergent for membrane proteins, including previously 
for PEDv M (Shenyang et al., 2007), and has applications in phase separation. Triton X-
100 is also used in VLP extraction protocols (Tseng et al., 2010). To keep detergent use 
consistent across experiments, and for all the above reasons, Triton X-100 was used in 
further experiments. Triton X-100 is able to solubilize protein complexes, increasingly so 
with incubation (Dencher and Heyn, 1978), and is known for its ability to solubilize the 
inner cell membrane of Gram-negative bacteria (Arnold and Linke, 2008). Both these 
properties may have helped in solubilizing ER-bound M-ELP.   
In contrast to the commercial kit, FEB contains antioxidant/reducing agents. Antioxidants 
prevent the oxidation of both proteins and phenolics. Antioxidants reduce the activity of 
polyphenol oxidases. This prevents the oxidation of polyphenols, which can bind to 
proteins, forming complexes and changing their structure (Laing and Christeller, 2004; 
Ozdal et al., 2013). When protein was extracted with the commercial kit, polyphenols 
may have bound to and inactivated proteins, potentially making the c-Myc tag 
inaccessible. FEB contains sodium L-ascorbate and PVPP, which binds to polyphenols, 
to alleviate this problem.  
Future work can explore the effect of adding DTT to the extraction buffer rather than in 
the sample buffer to prevent oxidation earlier, adding a larger range of protease inhibitors 
and the effects of sonicating protein extracts, using sound energy to break cell walls 
(Tang et al., 2002).  
4.3.1 Peroxidase 
Peroxidases are found in plants, animals, and microorganisms, and carry out a variety of 
roles in different physiological processes (Hiraga et al., 2001). One peroxidase that has 
been harnessed for its usefulness in research is horseradish peroxidase (HRP). HRP can 
catalyze the oxidation of luminol to 3-aminophthalate via intermediates. In the presence 
of substrate, HRP allows production of a detectable light signal. This application is useful 
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in Western blots. The primary antibody binds to a protein fixed to a specific spot on a 
membrane. When the secondary antibody is conjugated to HRP, it allows for the 
detection of the target protein upon incubation with a luminescent substrate (reviewed by 
Gazaryan et al., 1998). The anionic peroxidase (TOP) of N. tabacum was found to mimic 
HRP’s activity in this chemiluminescent reaction (Gazaryan et al., 1998). A BLAST 
search of the draft N. benthamiana genome for predicted proteins (Bombarely et al., 
2012) using the published sequence of N. tabacum’s anionic peroxidase (accession 
number: L02124) found one predicted protein, with a 93.73% sequence similarity to 
TOP, peroxidase 53. In comparison, TOP is 52% homologous to HRP, and retains 
function (Lagrimini et al., 1987). This indicates that peroxidase 53 may be the homologue 
to TOP in N. benthamiana. As peroxidases have conserved binding sites, peroxidase 53 is 
likely to retain function. Peroxidase 53 is predicted to have a molecular weight of 34.85 
kDa – the same size of the detected peroxidase (Figure 4). In addition, more peroxidase 
53 is observed in the soluble protein extract in comparison to the membrane protein 
extract (Figure 7). This correlates to data showing TOP is secreted extracellularly 
(Lagrimini et al., 1987).  
Tobacco peroxidases are involved in lignin formation, as well as in pathogen response. 
Anionic isozymes are upregulated in leaves infected with tobacco mosaic virus, though 
not in leaves that are wounded (Lagrimini and Rothstein, 1987). Overexpression of two 
anionic peroxidases which differ in post translational modifications in N. tabacum was 
observed to cause severe wilting (Lagrimini et al., 1990). E-ELP lanes show more 
accumulation of a peroxidase that runs between 50 and 75 kDa than any of the other 
PEDv proteins (Figure 13), and these leaves show yellowing (Figure 14). This peroxidase 
may be upregulated in response to E-ELP expression, and thus causing yellowing of the 
leaf tissue. This peroxidase of molecular weight about 60 kDa may be either a dimer of 
peroxidase 53, or a different peroxidase – but nonetheless it is correlated with the 
appearance of yellowing leaves. E causes ER stress in swine epithelial cells (Xu et al., 
2013); it may cause ER stress in plant leaves as well, and this ER stress may cause the 
upregulation of the higher molecular weight peroxidase. When M-ELP and E-ELP are 
co-expressed the amount of higher molecular weight peroxidase is reduced. E-ELP in 
VLPs may not cause as much ER stress. The infiltration process and viral components of 
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the expression vector also likely stimulate pathogen response, explaining why this higher 
molecular weight band was only seen in lanes of infiltrated leaves. 
After probing, membranes showed a similar sized 50-75 kDa band for E-ELP extracts, 
thought to be the dimer of E-ELP. To clarify whether this band was the putative E dimer 
or the above-mentioned peroxidase, the intensity of the light emitted from the membrane 
before and after probing was examined. Comparing Figures 13a and b, peroxidase bands 
that showed heavily before probing were in comparison faint afterwards. In addition, the 
amount of light emitted after probing was five times higher, despite being imaged for a 
sixth of the time, demonstrating that plant peroxidase was not emitting as strong a signal 
as HRP. Finally, mass spectrometry was performed on the putative dimer band, and E-
ELP was detected, indicating the dark band was due to E-ELP detection. Further 
credence is given knowing that TOP has a very low detection limit, does not need an 
enhancer substrate, and has a ten-fold higher signal intensity than HRP (Gazaryan et al., 
1998). The weak band observed in Figure 13a is likely a result of low amounts of 
peroxidase, as at pH 9, the pH of the ECL substrate used, TOP gives a higher light 
intensity than HRP (Hushpulian et al., 2007). While it must be considered that the ECL 
substrate used is optimized for HRP activity, TOP shows higher light intensity at all 
luminol concentrations, and higher stability in high H2O2 conditions (Gazaryan et al., 
1998), indicating weakened activity in comparison to HRP is unlikely because of buffer 
conditions.  
4.4 PEDv S, N, and E, and Co-Expression 
Accumulation of the S protein was not detected. This is not surprising, as others tried and 
failed to express it in plants (Zhu, Kaldis, Menassa, personal communication). S is a very 
large protein of calculated molecular weight of 169.4 kDa. All in planta work on 
expression of PEDv proteins has focussed on producing epitopes of the S protein (see 
1.1.3.3), and full length S protein has not been produced in plants.  
N-ELP has a predicted molecular weight of 66.6 kDa. While faint bands were observed in 
N-ELP samples, detected proteins were between 37 and 50 kDa. The presence of two 
distinct C-terminal fragments indicates that the fusion protein was likely produced, but 
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that there may be two protease cleavage sites. Testing a broader range of protease 
inhibitors in the extraction buffer may allow the detection of full length N-ELP in the 
future.  
Recombinant expression of PEDv E was successful, and E-ELP was observed at the 
predicted molecular weight of 26 kDa, and as a dimer slightly above 50 kDa. This was 
ideal as E has been necessary for VLP formation for other coronaviruses (described in 
4.5) (Vennema et al., 1996). Additionally, antibodies raised against MHV E neutralize 
viral infectivity in the presence of complement (Yu et al., 1994). The effect of PEDv E-
GFP has been monitored on porcine intestinal epithelial cells. PEDv E-GFP was observed 
to cause upregulation of Bcl-2, an anti-apoptotic molecule associated with cell survival. 
E-GFP was also observed to cause ER stress in the porcine cells however, and this may 
relate to the yellowing phenomenon seen after infiltration (Figure 14) (Xu et al., 2013).  
E-ELP was detected as both a monomer and dimer. Coronavirus E proteins demonstrate 
ion channel activity. However, with only one hydrophobic domain E would need to 
oligomerize to act as an ion channel (Ruch and Machamer, 2012). SARS-CoV E was 
predicted to form pentamers, and synthetic chemically produced SARS-CoV E was 
detected as a dimer, trimer, and pentamer (Torres et al., 2005). Oligomerization of 
biologically produced SARS-CoV E in the form of dimers and trimers was only observed 
under non-reducing conditions, indicating interaction through disulfide bonds (Liao et al., 
2004). IBV E also can form oligomers, and these dissociate into monomers when 
exposed to detergent or reducing agent (Westerbeck and Machamer, 2015).  
In this study E-ELP is observed as a monomer and dimer under detergent and reducing 
conditions in the extraction buffer and sample buffer. This gives further insight into the 
oligomerization of E. There is potential that the addition of ELP may have a stabilizing 
effecting on the E oligomer. If this is the case, it is unclear why the dimer is clearly 
visible instead of the trimers or pentamers observed in literature. 
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4.5 Virus-Like Particles 
4.5.1 Formation Requirements 
The minimum requirement for the formation of coronavirus-like particles has been the 
subject of ongoing research. With all reported VLPs requiring M, and most needing E as 
well, it was convenient that the two proteins that expressed well in this study were M-
ELP and E-ELP. As PEDv VLPs have not been previously reported, the minimum 
requirements were unknown. This study’s results show PEDv M is sufficient for VLP 
assembly. VLPs were also observed when the M-ELP and E-ELP were co-expressed. 
This is only the third time CoVLPs have been reported to be formed with just M.  
Research on TGEV had shown that VLPs could be formed without the S or N protein, 
indicating that the M and E proteins were both necessary and sufficient for VLP 
formation (Baudoux et al., 1998). For MHV it was found that M protein was not released 
into the medium unless it was co-expressed with E, using a vaccinia viral vector and 
OST7-1 (Mouse L) cells (de Haan et al., 1998), but that N and S are dispensable. This 
was striking as E is not abundant in the viral envelope – estimated to be found only 
twenty times in TGEV virions (Godet et al., 1992). Thus, rather than E forming an 
important part of the viral structure, it was thought that E was necessary in specific parts 
of the envelope to induce curvature in the intracellular membranes, resulting in particle 
formation (Vennema et al., 1996).  
However, research on SARS-CoV contradicted previous research on CoVLPs. This may 
be because SARS-CoV M is not as closely related to TGEV or MHV (Huang et al., 
2004), or potentially because it has a unique method of coronavirus assembly. While a 
report found M and E sufficient for SARS-CoVLP assembly (Ho et al., 2004), 
corroborating previous coronavirus research, a conflicting report claimed co-expression 
of M and N was both sufficient and necessary for VLP formation. However, these VLPs 
were observed intracellularly, and did not bud off unless S was co-expressed (Huang et 
al., 2004). While the study’s findings that M and N could form VLPs were an interesting 
advancement, the authors did not co-express M and E, making their claims about N being 
necessary unsatisfying. They did however express M alone, and found no VLPs were 
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formed. This potentially indicates an expression partner with M may be necessary for 
VLP assembly. That too was dispelled when SARS-CoVLPs were formed with the 
expression of only the M protein (Tseng et al., 2010). Recently it was found that 
expressing TGEV M alone also resulted in the formation of VLPs (Zhenhui et al., 2015), 
and that VLPs for IBV could be produced by co-expressing the M and S proteins (Liu et 
al., 2013) indicating that the formation requirements for CoVLPs are not as well 
understood as previously thought. Table 9 presents a brief non-exhaustive summary of 
CoVLP studies. 
E has also been found to release into sedimentable particles. Using sedimentation 
analysis+ it was found that E is released into vesicles from MHV in infected cells and 
when independently expressed, and in both cases sedimented at the same sucrose density. 
This density was lighter than that of MHV. Using flotation analysis, it was determined 
that E was an integral membrane protein in vesicles, though these were not visualized 
(Maeda et al., 1999). E has been reported to be released into sedimentable particles for 
IBV as well (Corse and Machamer, 2000). This emphasizes that E may be needed for 
VLP formation, as it may play an important role in the budding process of coronaviruses. 
For both MHV and IBV the efficiency of release was very low, and sedimented particles 
were not visualized. As M forms the characteristic structure of coronaviruses, these 
vesicles will be distinct from CoVLPs (see 4.5.2). Further research must be done to 
distinguish the relationship between E released in vesicles and E oligomers (see 4.5.4). 
Why other studies were only able to form VLPs when both M and E were co-expressed 
may be due to the system used for expression (i.e. animal cells vs plant cells). As 
research on SARS-CoV has conflicting reports on the need for E co-expression, 
differences in minimal requirements for VLP formation are likely not because of a 
difference in the viral assembly process, but more likely due to differences in 
experimental methods. Of the two studies that used HEK293T cells to produce SARS-
CoVLPs, one reports the assembly of M VLPs the other does not (Table 9). The two 
studies utilized the same transfection methods, cells, and similar growth mediums, and 
the study that found M VLPs obtained its expression vector from the lab that did not. The 
major difference then was the amount of plasmid transfected – the study that found M   
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Table 9. Protein expression configurations resulting in CoVLP assembly. 
Virus Protein(s) (Co-
)Expressed 
VLPs 
Observed 
Expression 
Platform 
Reference 
MHV ME/MES 
M, S, MS 
+ 
- 
OST7-11 (Vennema et al., 
1996) 
TGEV ME + RK13 cells2 (Baudoux et al., 
1998) 
SARS-CoV ME/MES 
M 
+ 
- 
Sf213 (Ho et al., 2004) 
SARS-CoV MN (didn’t bud 
off)/MNS/MNSE 
N/S/M 
+ 
 
- 
HEK293T4 (Huang et al., 
2004) 
SARS-CoV ME/MES 
M/E/S/MS/MESN 
+ 
- 
Sf95 (Mortola and 
Roy, 2004) 
SARS-CoV M/MN + HEK293T4 (Tseng et al., 
2010) 
IBV MS + Sf95 (Liu et al., 2013) 
1OST7-1, mouse L cells (mouse embryo fibroblast cells transformed with Maloney 
Sarcoma Virus and T7 RNA polymerase gene); 2Rk13 cells, rabbit kidney cells; 3Sf21, 
fall armyworm ovary cells; 4HEK293T, human embryonic kidney cells stably expressing 
SV40 large T antigen; 5Sf9, fall armyworm ovary cells. 
  
77 
  
VLPs transfected six times more DNA. Other differences include trypsinized cells before 
transfection, and concentrated VLPs before TEM analysis (Huang et al., 2004; Tseng et 
al., 2010). From this comparison, the difference in VLP detection may be because of 
amount of transfected DNA or cell transfection and handling methods. This would impact 
either VLP formation, or detection. 
 The insertion of a histidine tag after the initiating methionine has previously been shown 
to “strongly impair” VLP formation for MHV, suggesting that only minor insertions were 
permissible at the N-terminus (de Haan et al., 1998). The M-ELP fusion protein in this 
study contained a cleaved signal peptide after the initiating methionine, followed by an 
Xpress immunodetection tag, a restriction enzyme site, and a Gateway® cloning site 
before the amino acid sequence of the M protein. VLPs were still able to form, indicating 
that for PEDv, insertion restrictions may not be as severe. It remains to be seen if 
removing all insertions at the N-terminus can increase the number of VLPs formed. Use 
of an N-terminal signal peptide to target M-ELP and E-ELP to the ER may have helped 
with VLP formation, as coronaviruses typically bud off from the ERGIC (de Haan et al., 
2000). 
4.5.2 CoVLP Structure 
A distinct feature of coronaviruses is the thickness of the viral envelope, due to the matrix 
of M proteins in the envelope (Bárcena et al., 2009). The PEDv VLPs observed have the 
characteristic thick coronavirus envelope, averaging 9.3 nm and 10.1 nm, for M-ELP and 
M-ELP/E-ELP respectively (Figure 18), more than double the average thickness of 
biological membranes, approximately 4 nm. The envelope of MHV and TGEV are 7.8 ± 
0.7 nm and 7.4 ± 0.6 nm respectively (Bárcena et al., 2009), and this characteristic is 
observed for coronavirus-like particles (Neuman et al., 2011), as demonstrated in this 
study.  
4.5.3 CoVLP Size 
The results of this study show that VLPs produced with M-ELP and E-ELP are 
approximately 80 nm and VLPs with just M-ELP are smaller, approximately 50 nm. This 
is the first report comparing the size of ME VLPs with M VLPs. Both are smaller than 
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the average PEDv virion size, which has been reported to have a diameter ranging from 
60 nm (Ducatelle et al., 1982) to 190 nm, or just a 150 nm diameter (Hofmann and 
Wyler, 1989). The characteristic projections of the spike protein make up a large part of 
the coronavirus diameter, measuring 18 nm in length (Pensaert and De Bouck, 1978). 
While there is no existing data on PEDv VLPs, a look at the VLPs produced of other 
coronaviruses can provide insights on PEDv VLPs. SARS-CoV M VLPs were mostly 
found to be 40-50 nm in diameter, while MN VLPs were mostly found to have a diameter 
of 60-70 nm (Tseng et al., 2010). The absence of the nucleocapsid protein resulted in 
smaller VLPs. SARS-CoV virions typically have a diameter of 100 nm, indicating that 
MN VLPs may just be smaller by the size of the spikes on the virion surface.  
A similar result was reported for MHV. MSE VLPs have a slightly smaller diameter than 
natural virions, indicating presence of N may result in a larger size particle. This group 
also found not expressing S with ME made no difference to the particle diameter, 
(excluding spikes) (Vennema et al., 1996). However, another study on MHV reported 
that ME VLPs were bigger than MEN VLPs, and that both were larger than MHV virions 
with the full complement of proteins. The authors suggested that the interactions between 
the proteins led to smaller virions (Neuman et al., 2011). 
The lattice of M proteins is thought to have specific gaps for S and E proteins to integrate 
into the envelope. The absence of these interactions may result in a smaller diameter, as 
these gaps are closed due to lack of protein interaction. Similarly, lack of M-N 
interactions may also result in the smaller diameter of VLPs observed in this study. Why 
ME VLPs of the same coronavirus are observed to be either bigger or smaller than the 
corresponding virions may be correlated to why some groups have been able to produce 
VLPs with different minimum protein requirements. The potentially differing nature of 
M’s interactions may give rise to both differing particle sizes and what proteins are 
required to form VLPs. 
4.5.4 CoVLP Sedimentation Analysis 
Sucrose gradients are used for partial purification of VLPs, and for sedimentation 
analysis. PEDv M-ELP VLPs most heavily concentrated in the 40% sucrose fraction 
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(Figure 17a). PEDv virions have a density of 1.18 g/ml in sucrose (Hofmann and Wyler, 
1989), equivalent to approximately 40% sucrose, and as such, PEDv M tightly packs into 
VLPs that are similar to whole virions. Previously, SARS-CoV M VLPs were analyzed 
and found to concentrate at a density of 1.13 g/ml, corresponding to just over 30% 
sucrose (all % sucrose values in w/v) (Tseng et al., 2010). Unlike what is often observed 
for other CoVLPs, sedimentation analysis in this study did not result in recombinant 
protein only being detected in a few sucrose gradient fractions. M-ELP was found to 
sediment into every fraction. This likely indicates that the VLPs produced are very 
pleomorphic, similar to natural PEDv virions (Hofmann and Wyler, 1989). An alternate 
explanation may be that the accumulation of M-ELP was too high to allow for all the 
protein to efficiently bud into VLPs. The presence of M-ELP in the supernatant in 
particular may indicate that not all protein was incorporated into particles, leading to 
protein that did not sediment from the supernatant in particles, or may indicate VLPs 
formed that were not dense enough to enter the 30% sucrose fraction.  
When M-ELP and E-ELP were co-expressed, presence of M-ELP in the supernatant was 
reduced (Figure 17b). While the results show that M-ELP can independently form 
particles, the presence of E-ELP may allow for increased incorporation of the protein into 
VLPs. Fine tuning the ratios at which E-ELP and M-ELP are expressed may increase 
VLP assembly. Comparing levels of both M-ELP and the E-ELP monomer in the sucrose 
gradient fractions reveals that M-ELP/E-ELP VLPs concentrate most in the 40% fraction, 
like M-ELP VLPs and PEDv virions. TGEV ME VLPs have been compared to TGEV 
virions, and found to accumulate most highly in 27.8% and 33.9% sucrose respectively 
(Baudoux et al., 1998). Similarly MHV virions have been found to concentrate at the 
interface between 40% and 50% sucrose gradients, while ME VLPs concentrated at the 
30% and 40% interface (Vennema et al., 1996). With the discontinuous sucrose gradient 
used in this study, if VLPs and virions concentrated closer to 40% or 50% sucrose 
respectively, they would still be found in the same gradient. A continuous sucrose 
gradient may be used to compare the densities between VLPs and virions in a future 
study.  
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While the E-ELP monomer in this study accumulates most highly at the same point as M-
ELP, the E-ELP dimer peaks in the 30% sucrose fraction. E vesicles for MHV are 
observed at a density of 1.13 g/ml (Corse and Machamer, 2000), equivalent to 30% 
sucrose. This may indicate that E-ELP dimers bud off into vesicles with a smaller 
density, as was proposed for MHV. Alternatively, this may represent the sedimentation of 
higher molecular weight oligomers. Sedimentation analysis of IBV E on a 5 to 20% 
sucrose gradient showed an increase in IBV E oligomers at 20% sucrose (Westerbeck and 
Machamer, 2015). A wider gradient may have indicated E oligomers concentrating at a 
lighter gradient. The observation of E oligomers may be necessary for the release of E 
vesicles. IBV E oligomers were proposed to play a role in IBV MNE VLP formation, and 
IBV E monomers were not involved in this process (Westerbeck and Machamer, 2015). 
While in this study, E-ELP monomers sedimented at the same density as M-ELP, 
indicating the presence of E-ELP monomers in M-ELP/E-ELP VLPs, the presence of E-
ELP dimers in a lighter sucrose fraction potentially indicates that the dimers are driving 
release of E-ELP only vesicles. TEM analysis of extracts with just E is needed to 
determine the true nature of sedimented E protein. 
4.5.5 CoVLP Immunogenicity 
The ability to produce PEDv VLPs has direct implications on immunogenicity. The 
importance of VLP formation was demonstrated in a comparison of TGEV VLPs to 
TGEV proteins not in VLPs on the ability to induce alpha interferons (IFN-α), Type I 
interferons. IFN-α are an important component of the immune system, inducing the 
differentiation of APCs, and enhancing T- and B-cell functions (reviewed by Rizza et al., 
2011). Neither TGEV M in detergent-solubilized material nor TGEV M and S in protein-
liposome mixtures were able to induce interferons. However, TGEV ME VLPs were able 
to consistently induce IFN-α. As neither M nor E have a sequence motif for interferon 
induction, it is predicted that induction is caused by a structural feature of the VLPs 
(Baudoux et al., 1998). Classical adjuvants, such as complete Freund’s adjuvant, work in 
a process mediated by Type I interferons (reviewed by Rizza et al., 2011). The ability of 
CoVLPs to induce IFN-α may mean that these VLPs can be administered independently 
without the need of an adjuvant, and underline the importance of the specific VLP 
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structure. This could explain why even for other viruses the antibody response of VLPs is 
effective against a broader set of viral isolates, and results in a higher antibody titre than 
administering recombinant protein not in VLPs (Bright et al., 2007). CoVLPs have been 
demonstrated to effectively induce immune responses. IBV VLPs administered without 
adjuvants induce humoral immune responses comparable to inactivated IBV vaccine, and 
cellular immune responses that are significantly higher than those for inactivated IBV 
vaccine (Liu et al., 2013). The immunological importance of VLPs is clear, and animal 
trials are necessary to show if PEDv VLPs have similar immunogenicity. The successful 
production of PEDv VLPs gives hope for a low-cost effective PEDv vaccine that can be 
used to combat the disease worldwide.  
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5 Outlook 
The production of the first reported VLPs for PEDv, and the first plant-produced 
coronavirus-like particles is an exciting step forward for both efforts to curb the spread of 
PED and research on molecular farming. The combination of the conserved nature of the 
M protein (Zhang et al., 2012) and the immunogenic potential of VLPs to be effective 
against multiple viral strains (D'Aoust et al., 2008) indicate that M-ELP+E-ELP VLPs 
may provide an ideal vaccine solution for multiple markets. The quick turnaround time of 
the plant-based molecular farming platform means that even when genetically dissimilar 
PEDv strains arise, custom PEDv VLPs can rapidly be produced.  
To determine the viability of using the PEDv VLPs as vaccines, animal trials must be 
carried out. Future work may also include fine tuning the A. tumefaciens ratios of M-ELP 
and E-ELP to optimize VLP assembly, and troubleshooting the production of N-ELP and 
S-ELP in order to produce VLPs with all four structural proteins. Immunogold TEM 
using N-terminal antibodies for all three proteins embedded in the envelope can 
determine whether the proteins are being incorporated into VLPs. 
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Appendices 
Appendix A. Example of a dot blot used for quantification, with standards, M-ELP 
and p19 (negative control) tissue. 
 
 
  
98 
  
 
Appendix B. Mass spectrometry analysis of digested protein extracts.  
Recombinant Protein Amino Acid 
Sequences Detected 
Percent of Possible 
Coverage Detected 
Number of Peptide 
Spectrum Matches 
Full length M-ELP 194-203; 255-262; 
490-420 
9.9%-21.96% 3; 1; 1 
Truncated M-ELP 19-37; 176-194; 
194-203; 206-221; 
223-242; 409-420 
24.67%-61.65% 3; 2; 2; 1; 1; 1 
E-ELP (dimer band) 64-76 22.65% 2 
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